[{"path":"https://ahasoplakus.github.io/clinTables/articles/clinTables.html","id":"launch-the-application","dir":"Articles","previous_headings":"","what":"Launch the application","title":"Get Started with {clinTables}","text":"","code":"library(clinTables) run_app()"},{"path":"https://ahasoplakus.github.io/clinTables/articles/user-guide.html","id":"introduction","dir":"Articles","previous_headings":"","what":"Introduction","title":"User Guide","text":"article provides step--step user guide run clinTables application.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/articles/user-guide.html","id":"steps","dir":"Articles","previous_headings":"","what":"Steps","title":"User Guide","text":"Launch application Upload/Read data Preview Data Filters Setup Run Application","code":""},{"path":"https://ahasoplakus.github.io/clinTables/articles/user-guide.html","id":"launch","dir":"Articles","previous_headings":"Steps","what":"Launch application","title":"User Guide","text":"run_app() launch application application homepage load.","code":"library(clinTables) run_app()"},{"path":"https://ahasoplakus.github.io/clinTables/articles/user-guide.html","id":"readdata","dir":"Articles","previous_headings":"Steps","what":"Upload/Read in Data","title":"User Guide","text":"Switch Setup Homepage Turn Load Synthetic Data want run application using synthetic data available within package Click Upload Files button want load data want run application . (sas7bdat RDS formats accepted)","code":""},{"path":"https://ahasoplakus.github.io/clinTables/articles/user-guide.html","id":"note","dir":"Articles","previous_headings":"Steps > Upload/Read in Data","what":"Note","title":"User Guide","text":"ADaM standard datasets listed accepted clinTables v0.1.0 adsl: Subject-Level adae: Adverse Events adcm: Concomitant Medications admh: Medical History advs: Vital Signs adlb: Laboratory Analysis adeg: ECG Examinations  domain specific reports can accessed tabs placed navigation panel top application.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/articles/user-guide.html","id":"preview","dir":"Articles","previous_headings":"Steps","what":"Preview Data","title":"User Guide","text":"datasets read, Preview button enabled.   Click Preview button quickly glance data sets added analysis. modal window pop displaying names data sets loaded tabular format. Click expand button view specific data set.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/articles/user-guide.html","id":"setup","dir":"Articles","previous_headings":"Steps","what":"Filters Setup","title":"User Guide","text":"Expand ADSL Filters pill beneath Preview button add/remove adsl specific variables added filters. default SEX, RACE, ETHNIC, AGE, SITEID USUBJID variables selected. least one adsl variables need selected filter application work.   ADSL Filters appears left sidebar application run can applied filter domain specific reports.   Expand pills corresponding domain (ADAE, ADVS etc) add/remove domain specific variables added filters. example ADAE specific filters, AESEV AEACN added filters ADAE related reports.   ADAE Filters appear Table Options within Filter window ADAE related reports, application run. (Click  icon open filter window)","code":""},{"path":"https://ahasoplakus.github.io/clinTables/articles/user-guide.html","id":"run","dir":"Articles","previous_headings":"Steps","what":"Run Application","title":"User Guide","text":"Finally, run application clicking Run button.  Note: examples assume CDISC SDTM /ADaM format input unless otherwise specified.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"Sukalpo Saha. Maintainer, author.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Saha S (2024). clinTables: Clinical Trial Tables R. https://ahasoplakus.github.io/clinTables/, https://github.com/ahasoplakus/clinTables/.","code":"@Manual{,   title = {clinTables: Clinical Trial Tables in R},   author = {Sukalpo Saha},   year = {2024},   note = {https://ahasoplakus.github.io/clinTables/, https://github.com/ahasoplakus/clinTables/}, }"},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"our-pledge","dir":"","previous_headings":"","what":"Our Pledge","title":"Contributor Covenant Code of Conduct","text":"members, contributors, leaders pledge make participation community harassment-free experience everyone, regardless age, body size, visible invisible disability, ethnicity, sex characteristics, gender identity expression, level experience, education, socio-economic status, nationality, personal appearance, race, caste, color, religion, sexual identity orientation. pledge act interact ways contribute open, welcoming, diverse, inclusive, healthy community.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"our-standards","dir":"","previous_headings":"","what":"Our Standards","title":"Contributor Covenant Code of Conduct","text":"Examples behavior contributes positive environment community include: Demonstrating empathy kindness toward people respectful differing opinions, viewpoints, experiences Giving gracefully accepting constructive feedback Accepting responsibility apologizing affected mistakes, learning experience Focusing best just us individuals, overall community Examples unacceptable behavior include: use sexualized language imagery, sexual attention advances kind Trolling, insulting derogatory comments, personal political attacks Public private harassment Publishing others’ private information, physical email address, without explicit permission conduct reasonably considered inappropriate professional setting","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"enforcement-responsibilities","dir":"","previous_headings":"","what":"Enforcement Responsibilities","title":"Contributor Covenant Code of Conduct","text":"Community leaders responsible clarifying enforcing standards acceptable behavior take appropriate fair corrective action response behavior deem inappropriate, threatening, offensive, harmful. Community leaders right responsibility remove, edit, reject comments, commits, code, wiki edits, issues, contributions aligned Code Conduct, communicate reasons moderation decisions appropriate.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"scope","dir":"","previous_headings":"","what":"Scope","title":"Contributor Covenant Code of Conduct","text":"Code Conduct applies within community spaces, also applies individual officially representing community public spaces. Examples representing community include using official e-mail address, posting via official social media account, acting appointed representative online offline event.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"enforcement","dir":"","previous_headings":"","what":"Enforcement","title":"Contributor Covenant Code of Conduct","text":"Instances abusive, harassing, otherwise unacceptable behavior may reported community leaders responsible enforcement codeofconduct@rstudio.com. complaints reviewed investigated promptly fairly. community leaders obligated respect privacy security reporter incident.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"enforcement-guidelines","dir":"","previous_headings":"","what":"Enforcement Guidelines","title":"Contributor Covenant Code of Conduct","text":"Community leaders follow Community Impact Guidelines determining consequences action deem violation Code Conduct:","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"1-correction","dir":"","previous_headings":"Enforcement Guidelines","what":"1. Correction","title":"Contributor Covenant Code of Conduct","text":"Community Impact: Use inappropriate language behavior deemed unprofessional unwelcome community. Consequence: private, written warning community leaders, providing clarity around nature violation explanation behavior inappropriate. public apology may requested.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"2-warning","dir":"","previous_headings":"Enforcement Guidelines","what":"2. Warning","title":"Contributor Covenant Code of Conduct","text":"Community Impact: violation single incident series actions. Consequence: warning consequences continued behavior. interaction people involved, including unsolicited interaction enforcing Code Conduct, specified period time. includes avoiding interactions community spaces well external channels like social media. Violating terms may lead temporary permanent ban.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"3-temporary-ban","dir":"","previous_headings":"Enforcement Guidelines","what":"3. Temporary Ban","title":"Contributor Covenant Code of Conduct","text":"Community Impact: serious violation community standards, including sustained inappropriate behavior. Consequence: temporary ban sort interaction public communication community specified period time. public private interaction people involved, including unsolicited interaction enforcing Code Conduct, allowed period. Violating terms may lead permanent ban.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"4-permanent-ban","dir":"","previous_headings":"Enforcement Guidelines","what":"4. Permanent Ban","title":"Contributor Covenant Code of Conduct","text":"Community Impact: Demonstrating pattern violation community standards, including sustained inappropriate behavior, harassment individual, aggression toward disparagement classes individuals. Consequence: permanent ban sort public interaction within community.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"attribution","dir":"","previous_headings":"","what":"Attribution","title":"Contributor Covenant Code of Conduct","text":"Code Conduct adapted Contributor Covenant, version 2.1, available https://www.contributor-covenant.org/version/2/1/code_of_conduct.html. Community Impact Guidelines inspired [Mozilla’s code conduct enforcement ladder][https://github.com/mozilla/inclusion]. answers common questions code conduct, see FAQ https://www.contributor-covenant.org/faq. Translations available https://www.contributor-covenant.org/translations.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CONTRIBUTING.html","id":null,"dir":"","previous_headings":"","what":"Contributing to clinTables","title":"Contributing to clinTables","text":"outlines propose change clinTables. detailed info contributing , tidyverse packages, please see development contributing guide.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CONTRIBUTING.html","id":"fixing-typos","dir":"","previous_headings":"","what":"Fixing typos","title":"Contributing to clinTables","text":"can fix typos, spelling mistakes, grammatical errors documentation directly using GitHub web interface, long changes made source file. generally means ’ll need edit roxygen2 comments .R, .Rd file. can find .R file generates .Rd reading comment first line.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CONTRIBUTING.html","id":"bigger-changes","dir":"","previous_headings":"","what":"Bigger changes","title":"Contributing to clinTables","text":"want make bigger change, ’s good idea first file issue make sure someone team agrees ’s needed. ’ve found bug, please file issue illustrates bug minimal reprex (also help write unit test, needed).","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CONTRIBUTING.html","id":"pull-request-process","dir":"","previous_headings":"Bigger changes","what":"Pull request process","title":"Contributing to clinTables","text":"Fork package clone onto computer. haven’t done , recommend using usethis::create_from_github(\"ahasoplakus/clinTables\", fork = TRUE). Install development dependencies devtools::install_dev_deps(), make sure package passes R CMD check running devtools::check(). R CMD check doesn’t pass cleanly, ’s good idea ask help continuing. Create Git branch pull request (PR). recommend using usethis::pr_init(\"brief-description--change\"). Make changes, commit git, create PR running usethis::pr_push(), following prompts browser. title PR briefly describe change. body PR contain Fixes #issue-number. user-facing changes, add bullet top NEWS.md (.e. just first header). Follow style described https://style.tidyverse.org/news.html.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CONTRIBUTING.html","id":"code-style","dir":"","previous_headings":"Bigger changes","what":"Code style","title":"Contributing to clinTables","text":"New code follow tidyverse style guide. can use styler package apply styles, please don’t restyle code nothing PR. use roxygen2, Markdown syntax, documentation. use testthat unit tests. Contributions test cases included easier accept.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CONTRIBUTING.html","id":"code-of-conduct","dir":"","previous_headings":"","what":"Code of Conduct","title":"Contributing to clinTables","text":"Please note clinTables project released Contributor Code Conduct. contributing project agree abide terms.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/index.html","id":"clintables-","dir":"","previous_headings":"","what":"Clinical Trial Tables in R","title":"Clinical Trial Tables in R","text":"clinTables shiny application visualize standard safety tables used Clinical Trials","code":""},{"path":"https://ahasoplakus.github.io/clinTables/index.html","id":"installation","dir":"","previous_headings":"","what":"Installation","title":"Clinical Trial Tables in R","text":"Latest dev version Find app deployed Run library(clinTables) access exported functions clinTables help reproducing analysis performed app. , can run application locally using:","code":"remotes::install_github(\"ahasoplakus/clinTables\", ref = \"devel\", build_vignettes = TRUE) # Launch the application run_app()"},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":null,"dir":"","previous_headings":"","what":"Apache License","title":"Apache License","text":"Version 2.0, January 2004 <http://www.apache.org/licenses/>","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"1-definitions","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"1. Definitions","title":"Apache License","text":"“License” shall mean terms conditions use, reproduction, distribution defined Sections 1 9 document. “Licensor” shall mean copyright owner entity authorized copyright owner granting License. “Legal Entity” shall mean union acting entity entities control, controlled , common control entity. purposes definition, “control” means () power, direct indirect, cause direction management entity, whether contract otherwise, (ii) ownership fifty percent (50%) outstanding shares, (iii) beneficial ownership entity. “” (“”) shall mean individual Legal Entity exercising permissions granted License. “Source” form shall mean preferred form making modifications, including limited software source code, documentation source, configuration files. “Object” form shall mean form resulting mechanical transformation translation Source form, including limited compiled object code, generated documentation, conversions media types. “Work” shall mean work authorship, whether Source Object form, made available License, indicated copyright notice included attached work (example provided Appendix ). “Derivative Works” shall mean work, whether Source Object form, based (derived ) Work editorial revisions, annotations, elaborations, modifications represent, whole, original work authorship. purposes License, Derivative Works shall include works remain separable , merely link (bind name) interfaces , Work Derivative Works thereof. “Contribution” shall mean work authorship, including original version Work modifications additions Work Derivative Works thereof, intentionally submitted Licensor inclusion Work copyright owner individual Legal Entity authorized submit behalf copyright owner. purposes definition, “submitted” means form electronic, verbal, written communication sent Licensor representatives, including limited communication electronic mailing lists, source code control systems, issue tracking systems managed , behalf , Licensor purpose discussing improving Work, excluding communication conspicuously marked otherwise designated writing copyright owner “Contribution.” “Contributor” shall mean Licensor individual Legal Entity behalf Contribution received Licensor subsequently incorporated within Work.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"2-grant-of-copyright-license","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"2. Grant of Copyright License","title":"Apache License","text":"Subject terms conditions License, Contributor hereby grants perpetual, worldwide, non-exclusive, -charge, royalty-free, irrevocable copyright license reproduce, prepare Derivative Works , publicly display, publicly perform, sublicense, distribute Work Derivative Works Source Object form.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"3-grant-of-patent-license","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"3. Grant of Patent License","title":"Apache License","text":"Subject terms conditions License, Contributor hereby grants perpetual, worldwide, non-exclusive, -charge, royalty-free, irrevocable (except stated section) patent license make, made, use, offer sell, sell, import, otherwise transfer Work, license applies patent claims licensable Contributor necessarily infringed Contribution(s) alone combination Contribution(s) Work Contribution(s) submitted. institute patent litigation entity (including cross-claim counterclaim lawsuit) alleging Work Contribution incorporated within Work constitutes direct contributory patent infringement, patent licenses granted License Work shall terminate date litigation filed.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"4-redistribution","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"4. Redistribution","title":"Apache License","text":"may reproduce distribute copies Work Derivative Works thereof medium, without modifications, Source Object form, provided meet following conditions: () must give recipients Work Derivative Works copy License; (b) must cause modified files carry prominent notices stating changed files; (c) must retain, Source form Derivative Works distribute, copyright, patent, trademark, attribution notices Source form Work, excluding notices pertain part Derivative Works; (d) Work includes “NOTICE” text file part distribution, Derivative Works distribute must include readable copy attribution notices contained within NOTICE file, excluding notices pertain part Derivative Works, least one following places: within NOTICE text file distributed part Derivative Works; within Source form documentation, provided along Derivative Works; , within display generated Derivative Works, wherever third-party notices normally appear. contents NOTICE file informational purposes modify License. may add attribution notices within Derivative Works distribute, alongside addendum NOTICE text Work, provided additional attribution notices construed modifying License. may add copyright statement modifications may provide additional different license terms conditions use, reproduction, distribution modifications, Derivative Works whole, provided use, reproduction, distribution Work otherwise complies conditions stated License.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"5-submission-of-contributions","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"5. Submission of Contributions","title":"Apache License","text":"Unless explicitly state otherwise, Contribution intentionally submitted inclusion Work Licensor shall terms conditions License, without additional terms conditions. Notwithstanding , nothing herein shall supersede modify terms separate license agreement may executed Licensor regarding Contributions.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"6-trademarks","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"6. Trademarks","title":"Apache License","text":"License grant permission use trade names, trademarks, service marks, product names Licensor, except required reasonable customary use describing origin Work reproducing content NOTICE file.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"7-disclaimer-of-warranty","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"7. Disclaimer of Warranty","title":"Apache License","text":"Unless required applicable law agreed writing, Licensor provides Work (Contributor provides Contributions) “” BASIS, WITHOUT WARRANTIES CONDITIONS KIND, either express implied, including, without limitation, warranties conditions TITLE, NON-INFRINGEMENT, MERCHANTABILITY, FITNESS PARTICULAR PURPOSE. solely responsible determining appropriateness using redistributing Work assume risks associated exercise permissions License.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"8-limitation-of-liability","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"8. Limitation of Liability","title":"Apache License","text":"event legal theory, whether tort (including negligence), contract, otherwise, unless required applicable law (deliberate grossly negligent acts) agreed writing, shall Contributor liable damages, including direct, indirect, special, incidental, consequential damages character arising result License use inability use Work (including limited damages loss goodwill, work stoppage, computer failure malfunction, commercial damages losses), even Contributor advised possibility damages.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"9-accepting-warranty-or-additional-liability","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"9. Accepting Warranty or Additional Liability","title":"Apache License","text":"redistributing Work Derivative Works thereof, may choose offer, charge fee , acceptance support, warranty, indemnity, liability obligations /rights consistent License. However, accepting obligations, may act behalf sole responsibility, behalf Contributor, agree indemnify, defend, hold Contributor harmless liability incurred , claims asserted , Contributor reason accepting warranty additional liability. END TERMS CONDITIONS","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"appendix-how-to-apply-the-apache-license-to-your-work","dir":"","previous_headings":"","what":"APPENDIX: How to apply the Apache License to your work","title":"Apache License","text":"apply Apache License work, attach following boilerplate notice, fields enclosed brackets [] replaced identifying information. (Don’t include brackets!) text enclosed appropriate comment syntax file format. also recommend file class name description purpose included “printed page” copyright notice easier identification within third-party archives.","code":"Copyright [yyyy] [name of copyright owner]  Licensed under the Apache License, Version 2.0 (the \"License\"); you may not use this file except in compliance with the License. You may obtain a copy of the License at    http://www.apache.org/licenses/LICENSE-2.0  Unless required by applicable law or agreed to in writing, software distributed under the License is distributed on an \"AS IS\" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied. See the License for the specific language governing permissions and limitations under the License."},{"path":"https://ahasoplakus.github.io/clinTables/reference/adae.html","id":null,"dir":"Reference","previous_headings":"","what":"Adverse Events Dataset. — adae","title":"Adverse Events Dataset. — adae","text":"Adverse Events Dataset.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/adae.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Adverse Events Dataset. — adae","text":"","code":"data(adae)"},{"path":"https://ahasoplakus.github.io/clinTables/reference/adae.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Adverse Events Dataset. — adae","text":"Data frame 1934 features 92 fields","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/adae.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Adverse Events Dataset. — adae","text":"https://github.com/insightsengineering/random.cdisc.data/tree/main/data","code":""},{"path":[]},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/add_adae_flags.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Add Flags to ADAE — add_adae_flags","text":"","code":"add_adae_flags(df)"},{"path":"https://ahasoplakus.github.io/clinTables/reference/add_adae_flags.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Add Flags to ADAE — add_adae_flags","text":"df (data.frame) ADAE dataset.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/add_adae_flags.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Add Flags to ADAE — add_adae_flags","text":"ADAE dataset added flags","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/add_adae_flags.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Add Flags to ADAE — add_adae_flags","text":"","code":"suppressMessages(library(dplyr))  adsl <- pharmaverseadam::adsl adae <- pharmaverseadam::adae  adae_ <- suppressMessages(add_adae_flags(adae))  adae_ |>   select(c(\"USUBJID\", setdiff(names(adae_), names(adae)))) |>   slice_head(n = 5) #> # A tibble: 5 x 16 #>   USUBJID     SER   SAEFATAL SAELIFE SAEHOSP SAEDISAB SAECONG SAEMIE WD    WDSM  #>   <chr>       <lgl> <lgl>    <lgl>   <lgl>   <lgl>    <lgl>   <lgl>  <lgl> <lgl> #> 1 01-701-1015 FALSE FALSE    FALSE   FALSE   FALSE    FALSE   FALSE  NA    FALSE #> 2 01-701-1015 FALSE FALSE    FALSE   FALSE   FALSE    FALSE   FALSE  NA    FALSE #> 3 01-701-1015 FALSE FALSE    FALSE   FALSE   FALSE    FALSE   FALSE  NA    FALSE #> 4 01-701-1023 FALSE FALSE    FALSE   FALSE   FALSE    FALSE   FALSE  NA    FALSE #> 5 01-701-1023 FALSE FALSE    FALSE   FALSE   FALSE    FALSE   FALSE  NA    FALSE #> # i 6 more variables: AEINT <lgl>, AERED <lgl>, AED <lgl>, AEMIE <lgl>, #> #   CTC35 <lgl>, CTC45 <lgl>"},{"path":"https://ahasoplakus.github.io/clinTables/reference/adlb.html","id":null,"dir":"Reference","previous_headings":"","what":"Laboratory Analysis Dataset. — adlb","title":"Laboratory Analysis Dataset. — adlb","text":"Laboratory Analysis Dataset.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/adlb.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Laboratory Analysis Dataset. — adlb","text":"","code":"data(adlb)"},{"path":"https://ahasoplakus.github.io/clinTables/reference/adlb.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Laboratory Analysis Dataset. — adlb","text":"Data frame 8400 features 102 fields","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/adlb.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Laboratory Analysis Dataset. — adlb","text":"https://github.com/insightsengineering/random.cdisc.data/tree/main/data","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/adsl.html","id":null,"dir":"Reference","previous_headings":"","what":"Subject Level Analysis Dataset. — adsl","title":"Subject Level Analysis Dataset. — adsl","text":"Subject Level Analysis Dataset.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/adsl.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Subject Level Analysis Dataset. — adsl","text":"","code":"data(adsl)"},{"path":"https://ahasoplakus.github.io/clinTables/reference/adsl.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Subject Level Analysis Dataset. — adsl","text":"Data frame 400 features 55 fields","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/adsl.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Subject Level Analysis Dataset. — adsl","text":"https://github.com/insightsengineering/random.cdisc.data/tree/main/data","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/advs.html","id":null,"dir":"Reference","previous_headings":"","what":"Vital Signs Dataset. — advs","title":"Vital Signs Dataset. — advs","text":"Vital Signs Dataset.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/advs.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Vital Signs Dataset. — advs","text":"","code":"data(advs)"},{"path":"https://ahasoplakus.github.io/clinTables/reference/advs.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Vital Signs Dataset. — advs","text":"Data frame 16800 features 87 fields","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/advs.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Vital Signs Dataset. — advs","text":"https://github.com/insightsengineering/random.cdisc.data/tree/main/data","code":""},{"path":[]},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_by_sev_tox.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Adverse Events Table by Body System and Severity/Toxicity — build_adae_by_sev_tox","text":"","code":"build_adae_by_sev_tox(   adae,   colsby = \"ARM\",   filter_cond = NULL,   grade_val = \"AESEV\",   class_val = \"AESOC\",   term_val = \"AEDECOD\" )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_by_sev_tox.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Adverse Events Table by Body System and Severity/Toxicity — build_adae_by_sev_tox","text":"adae (data.frame) ADAE dataset. colsby (character) Variable used split table columns. filter_cond (character) Filtering condition required df_adae. grade_val (character) AE Severity AE Toxicity Grade .e. AESEV AETOXGR class_val (character) System Organ Class/Body System Class .e. AESOC AEBODSYS term_val (character) Dictionary Derived Term .e. AEDECOD AETERM.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_by_sev_tox.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Adverse Events Table by Body System and Severity/Toxicity — build_adae_by_sev_tox","text":"rtable object","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_by_sev_tox.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Adverse Events Table by Body System and Severity/Toxicity — build_adae_by_sev_tox","text":"Primary System Organ Class     Dictionary-Derived Term Placebo (N=86) Xanomeline High Dose (N=84) Xanomeline Low Dose (N=84) Patients (N=306) Total number patients least one adverse event 65 (75.6%) 75 (89.3%) 77 (91.7%) 217 (70.9%) Total number adverse events 281 429 412 1122 CARDIAC DISORDERS     ATRIAL FIBRILLATION     MILD 0 2 (2.4%) 0 2 (0.7%) MODERATE 1 (1.2%) 0 1 (1.2%) 2 (0.7%) SEVERE 0 1 (1.2%) 0 1 (0.3%) ATRIAL FLUTTER     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 ATRIAL HYPERTROPHY     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 ATRIOVENTRICULAR BLOCK FIRST DEGREE     MILD 1 (1.2%) 0 1 (1.2%) 2 (0.7%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 ATRIOVENTRICULAR BLOCK SECOND DEGREE     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 BRADYCARDIA     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 BUNDLE BRANCH BLOCK LEFT     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 BUNDLE BRANCH BLOCK RIGHT     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 CARDIAC DISORDER     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 CARDIAC FAILURE CONGESTIVE     MILD 0 0 0 0 MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 MYOCARDIAL INFARCTION     MILD 1 (1.2%) 3 (3.6%) 2 (2.4%) 6 (2.0%) MODERATE 1 (1.2%) 1 (1.2%) 0 2 (0.7%) SEVERE 2 (2.3%) 0 0 2 (0.7%) PALPITATIONS     MILD 0 0 0 0 MODERATE 0 0 2 (2.4%) 2 (0.7%) SEVERE 0 0 0 0 SINUS ARRHYTHMIA     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 SINUS BRADYCARDIA     MILD 1 (1.2%) 4 (4.8%) 6 (7.1%) 11 (3.6%) MODERATE 1 (1.2%) 4 (4.8%) 1 (1.2%) 6 (2.0%) SEVERE 0 0 0 0 SUPRAVENTRICULAR EXTRASYSTOLES     MILD 1 (1.2%) 1 (1.2%) 1 (1.2%) 3 (1.0%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 SUPRAVENTRICULAR TACHYCARDIA     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 TACHYCARDIA     MILD 0 0 0 0 MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 VENTRICULAR EXTRASYSTOLES     MILD 0 1 (1.2%) 1 (1.2%) 2 (0.7%) MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 VENTRICULAR HYPERTROPHY     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 WOLFF-PARKINSON-WHITE SYNDROME     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 CONGENITAL, FAMILIAL GENETIC DISORDERS     VENTRICULAR SEPTAL DEFECT     MILD 0 2 (2.4%) 0 2 (0.7%) MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 EAR LABYRINTH DISORDERS     CERUMEN IMPACTION     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 EAR PAIN     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 VERTIGO     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 1 (1.2%) 2 (0.7%) SEVERE 0 0 0 0 EYE DISORDERS     CONJUNCTIVAL HAEMORRHAGE     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 CONJUNCTIVITIS     MILD 0 0 0 0 MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 EYE ALLERGY     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 EYE PRURITUS     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 EYE SWELLING     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 VISION BLURRED     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 GASTROINTESTINAL DISORDERS     ABDOMINAL DISCOMFORT     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 ABDOMINAL PAIN     MILD 1 (1.2%) 0 2 (2.4%) 3 (1.0%) MODERATE 0 1 (1.2%) 1 (1.2%) 2 (0.7%) SEVERE 0 0 0 0 CONSTIPATION     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 DIARRHOEA     MILD 9 (10.5%) 2 (2.4%) 4 (4.8%) 15 (4.9%) MODERATE 0 2 (2.4%) 0 2 (0.7%) SEVERE 0 0 0 0 DYSPEPSIA     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 DYSPHAGIA     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 FLATULENCE     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 GASTROINTESTINAL HAEMORRHAGE     MILD 0 0 0 0 MODERATE 0 0 0 0 SEVERE 0 1 (1.2%) 0 1 (0.3%) GASTROOESOPHAGEAL REFLUX DISEASE     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 GLOSSITIS     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 HIATUS HERNIA     MILD 0 0 0 0 MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 NAUSEA     MILD 2 (2.3%) 5 (6.0%) 2 (2.4%) 9 (2.9%) MODERATE 1 (1.2%) 0 1 (1.2%) 2 (0.7%) SEVERE 0 1 (1.2%) 0 1 (0.3%) RECTAL HAEMORRHAGE     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 SALIVARY HYPERSECRETION     MILD 0 4 (4.8%) 0 4 (1.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 STOMACH DISCOMFORT     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 VOMITING     MILD 2 (2.3%) 5 (6.0%) 2 (2.4%) 9 (2.9%) MODERATE 1 (1.2%) 2 (2.4%) 1 (1.2%) 4 (1.3%) SEVERE 0 0 0 0 GENERAL DISORDERS ADMINISTRATION SITE CONDITIONS     APPLICATION SITE BLEEDING     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 APPLICATION SITE DERMATITIS     MILD 5 (5.8%) 2 (2.4%) 4 (4.8%) 11 (3.6%) MODERATE 0 5 (6.0%) 4 (4.8%) 9 (2.9%) SEVERE 0 0 1 (1.2%) 1 (0.3%) APPLICATION SITE DESQUAMATION     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 APPLICATION SITE DISCHARGE     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 APPLICATION SITE DISCOLOURATION     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 APPLICATION SITE ERYTHEMA     MILD 3 (3.5%) 9 (10.7%) 4 (4.8%) 16 (5.2%) MODERATE 0 6 (7.1%) 6 (7.1%) 12 (3.9%) SEVERE 0 0 2 (2.4%) 2 (0.7%) APPLICATION SITE INDURATION     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 APPLICATION SITE IRRITATION     MILD 1 (1.2%) 3 (3.6%) 3 (3.6%) 7 (2.3%) MODERATE 2 (2.3%) 6 (7.1%) 3 (3.6%) 11 (3.6%) SEVERE 0 0 3 (3.6%) 3 (1.0%) APPLICATION SITE PAIN     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 APPLICATION SITE PERSPIRATION     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 APPLICATION SITE PRURITUS     MILD 5 (5.8%) 10 (11.9%) 13 (15.5%) 28 (9.2%) MODERATE 1 (1.2%) 12 (14.3%) 8 (9.5%) 21 (6.9%) SEVERE 0 0 1 (1.2%) 1 (0.3%) APPLICATION SITE REACTION     MILD 0 0 0 0 MODERATE 1 (1.2%) 1 (1.2%) 0 2 (0.7%) SEVERE 0 0 0 0 APPLICATION SITE SWELLING     MILD 0 1 (1.2%) 1 (1.2%) 2 (0.7%) MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 APPLICATION SITE URTICARIA     MILD 0 0 2 (2.4%) 2 (0.7%) MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 APPLICATION SITE VESICLES     MILD 1 (1.2%) 2 (2.4%) 3 (3.6%) 6 (2.0%) MODERATE 0 4 (4.8%) 1 (1.2%) 5 (1.6%) SEVERE 0 0 0 0 APPLICATION SITE WARMTH     MILD 0 0 0 0 MODERATE 0 0 0 0 SEVERE 0 0 1 (1.2%) 1 (0.3%) ASTHENIA     MILD 0 0 0 0 MODERATE 1 (1.2%) 1 (1.2%) 0 2 (0.7%) SEVERE 0 0 0 0 CHEST DISCOMFORT     MILD 0 2 (2.4%) 0 2 (0.7%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 CHEST PAIN     MILD 0 2 (2.4%) 0 2 (0.7%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 CHILLS     MILD 0 1 (1.2%) 1 (1.2%) 2 (0.7%) MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 FATIGUE     MILD 1 (1.2%) 5 (6.0%) 3 (3.6%) 9 (2.9%) MODERATE 0 0 2 (2.4%) 2 (0.7%) SEVERE 0 0 0 0 FEELING ABNORMAL     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 FEELING COLD     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 INFLAMMATION     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 MALAISE     MILD 0 1 (1.2%) 1 (1.2%) 2 (0.7%) MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 OEDEMA     MILD 0 0 2 (2.4%) 2 (0.7%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 OEDEMA PERIPHERAL     MILD 2 (2.3%) 1 (1.2%) 0 3 (1.0%) MODERATE 0 1 (1.2%) 1 (1.2%) 2 (0.7%) SEVERE 0 0 0 0 PAIN     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 PYREXIA     MILD 2 (2.3%) 1 (1.2%) 0 3 (1.0%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 SECRETION DISCHARGE     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 SUDDEN DEATH     MILD 0 0 0 0 MODERATE 0 0 0 0 SEVERE 0 0 1 (1.2%) 1 (0.3%) SWELLING     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 ULCER     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 HEPATOBILIARY DISORDERS     HYPERBILIRUBINAEMIA     MILD 0 0 0 0 MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 IMMUNE SYSTEM DISORDERS     HYPERSENSITIVITY     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 INFECTIONS INFESTATIONS     BRONCHITIS     MILD 0 0 0 0 MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 CELLULITIS     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 CERVICITIS     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 CYSTITIS     MILD 1 (1.2%) 1 (1.2%) 0 2 (0.7%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 EAR INFECTION     MILD 2 (2.3%) 0 0 2 (0.7%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 GASTROENTERITIS VIRAL     MILD 0 0 0 0 MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 HORDEOLUM     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 INFLUENZA     MILD 1 (1.2%) 1 (1.2%) 1 (1.2%) 3 (1.0%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 LOCALISED INFECTION     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 LOWER RESPIRATORY TRACT INFECTION     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 NASOPHARYNGITIS     MILD 1 (1.2%) 5 (6.0%) 3 (3.6%) 9 (2.9%) MODERATE 1 (1.2%) 1 (1.2%) 0 2 (0.7%) SEVERE 0 0 1 (1.2%) 1 (0.3%) PNEUMONIA     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 RHINITIS     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 UPPER RESPIRATORY TRACT INFECTION     MILD 4 (4.7%) 2 (2.4%) 1 (1.2%) 7 (2.3%) MODERATE 2 (2.3%) 1 (1.2%) 0 3 (1.0%) SEVERE 0 0 0 0 URINARY TRACT INFECTION     MILD 2 (2.3%) 1 (1.2%) 0 3 (1.0%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 VAGINAL MYCOSIS     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 VIRAL INFECTION     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 INJURY, POISONING PROCEDURAL COMPLICATIONS     CONTUSION     MILD 1 (1.2%) 2 (2.4%) 0 3 (1.0%) MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 EXCORIATION     MILD 2 (2.3%) 0 0 2 (0.7%) MODERATE 0 1 (1.2%) 1 (1.2%) 2 (0.7%) SEVERE 0 0 0 0 FACIAL BONES FRACTURE     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 FALL     MILD 1 (1.2%) 1 (1.2%) 1 (1.2%) 3 (1.0%) MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 HIP FRACTURE     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 1 (1.2%) 1 (1.2%) 0 2 (0.7%) JOINT DISLOCATION     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 SKIN LACERATION     MILD 1 (1.2%) 0 1 (1.2%) 2 (0.7%) MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 WOUND     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 INVESTIGATIONS     BIOPSY     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 BIOPSY PROSTATE     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 BLOOD ALKALINE PHOSPHATASE INCREASED     MILD 0 0 0 0 MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 BLOOD CHOLESTEROL INCREASED     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 BLOOD CREATINE PHOSPHOKINASE INCREASED     MILD 0 0 0 0 MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 BLOOD GLUCOSE INCREASED     MILD 0 1 (1.2%) 1 (1.2%) 2 (0.7%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 BLOOD URINE PRESENT     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 BODY TEMPERATURE INCREASED     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 CYSTOSCOPY     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 ELECTROCARDIOGRAM ST SEGMENT DEPRESSION     MILD 4 (4.7%) 0 1 (1.2%) 5 (1.6%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED     MILD 1 (1.2%) 0 1 (1.2%) 2 (0.7%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 ELECTROCARDIOGRAM T WAVE INVERSION     MILD 2 (2.3%) 1 (1.2%) 1 (1.2%) 4 (1.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 HEART RATE INCREASED     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 HEART RATE IRREGULAR     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 NASAL MUCOSA BIOPSY     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 WEIGHT DECREASED     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 METABOLISM NUTRITION DISORDERS     DECREASED APPETITE     MILD 0 0 0 0 MODERATE 1 (1.2%) 1 (1.2%) 0 2 (0.7%) SEVERE 0 0 0 0 DEHYDRATION     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 DIABETES MELLITUS     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 FOOD CRAVING     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 HYPONATRAEMIA     MILD 0 0 0 0 MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 INCREASED APPETITE     MILD 1 (1.2%) 1 (1.2%) 0 2 (0.7%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 MUSCULOSKELETAL CONNECTIVE TISSUE DISORDERS     ARTHRALGIA     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 1 (1.2%) 2 (2.4%) 3 (1.0%) SEVERE 0 0 0 0 ARTHRITIS     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 BACK PAIN     MILD 1 (1.2%) 2 (2.4%) 0 3 (1.0%) MODERATE 0 1 (1.2%) 1 (1.2%) 2 (0.7%) SEVERE 0 0 0 0 FLANK PAIN     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 MUSCLE SPASMS     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 1 (1.2%) 1 (0.3%) MUSCULAR WEAKNESS     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 MYALGIA     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 PAIN EXTREMITY     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 SHOULDER PAIN     MILD 0 0 2 (2.4%) 2 (0.7%) MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 NEOPLASMS BENIGN, MALIGNANT UNSPECIFIED (INCL CYSTS POLYPS)     COLON CANCER     MILD 0 0 0 0 MODERATE 0 0 0 0 SEVERE 0 0 1 (1.2%) 1 (0.3%) MALIGNANT FIBROUS HISTIOCYTOMA     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 PROSTATE CANCER     MILD 0 0 0 0 MODERATE 0 0 0 0 SEVERE 0 1 (1.2%) 0 1 (0.3%) NERVOUS SYSTEM DISORDERS     AMNESIA     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 BALANCE DISORDER     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 BURNING SENSATION     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 COGNITIVE DISORDER     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 COMPLEX PARTIAL SEIZURES     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 COORDINATION ABNORMAL     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 DIZZINESS     MILD 2 (2.3%) 7 (8.3%) 5 (6.0%) 14 (4.6%) MODERATE 0 3 (3.6%) 3 (3.6%) 6 (2.0%) SEVERE 0 1 (1.2%) 0 1 (0.3%) HEADACHE     MILD 3 (3.5%) 4 (4.8%) 2 (2.4%) 9 (2.9%) MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 1 (1.2%) 1 (0.3%) HEMIANOPIA HOMONYMOUS     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 HYPERSOMNIA     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 LETHARGY     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 1 (1.2%) 2 (0.7%) SEVERE 0 0 0 0 PARAESTHESIA     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 PARAESTHESIA ORAL     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 PARKINSON'S DISEASE     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 PAROSMIA     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 PARTIAL SEIZURES SECONDARY GENERALISATION     MILD 0 0 0 0 MODERATE 0 0 0 0 SEVERE 0 1 (1.2%) 0 1 (0.3%) PSYCHOMOTOR HYPERACTIVITY     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 SOMNOLENCE     MILD 0 1 (1.2%) 1 (1.2%) 2 (0.7%) MODERATE 2 (2.3%) 0 2 (2.4%) 4 (1.3%) SEVERE 0 0 0 0 STUPOR     MILD 0 0 0 0 MODERATE 0 0 0 0 SEVERE 0 0 1 (1.2%) 1 (0.3%) SYNCOPE     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 2 (2.4%) 1 (1.2%) 3 (1.0%) SEVERE 0 1 (1.2%) 2 (2.4%) 3 (1.0%) SYNCOPE VASOVAGAL     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 TRANSIENT ISCHAEMIC ATTACK     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 1 (1.2%) 1 (1.2%) 2 (0.7%) PSYCHIATRIC DISORDERS     AGITATION     MILD 2 (2.3%) 0 0 2 (0.7%) MODERATE 0 1 (1.2%) 1 (1.2%) 2 (0.7%) SEVERE 0 0 1 (1.2%) 1 (0.3%) ANXIETY     MILD 0 0 3 (3.6%) 3 (1.0%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 COMPLETED SUICIDE     MILD 0 0 0 0 MODERATE 0 0 0 0 SEVERE 1 (1.2%) 0 0 1 (0.3%) CONFUSIONAL STATE     MILD 1 (1.2%) 1 (1.2%) 0 2 (0.7%) MODERATE 1 (1.2%) 0 3 (3.6%) 4 (1.3%) SEVERE 0 0 0 0 DELIRIUM     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 DELUSION     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 DEPRESSED MOOD     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 DISORIENTATION     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 HALLUCINATION     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 HALLUCINATION, VISUAL     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 INSOMNIA     MILD 2 (2.3%) 2 (2.4%) 0 4 (1.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 IRRITABILITY     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 LIBIDO DECREASED     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 LISTLESS     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 NIGHTMARE     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 RESTLESSNESS     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 RENAL URINARY DISORDERS     CALCULUS URETHRAL     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0 DYSURIA     MILD 1 (1.2%) 0 1 (1.2%) 2 (0.7%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 INCONTINENCE     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 MICTURITION URGENCY     MILD 1 (1.2%) 1 (1.2%) 1 (1.2%) 3 (1.0%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 NEPHROLITHIASIS     MILD 0 0 0 0 MODERATE 1 (1.2%) 1 (1.2%) 0 2 (0.7%) SEVERE 0 0 0 0 POLLAKIURIA     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 REPRODUCTIVE SYSTEM BREAST DISORDERS     BENIGN PROSTATIC HYPERPLASIA     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 1 (1.2%) 0 0 1 (0.3%) PELVIC PAIN     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 RESPIRATORY, THORACIC MEDIASTINAL DISORDERS     ALLERGIC GRANULOMATOUS ANGIITIS     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 COUGH     MILD 1 (1.2%) 3 (3.6%) 3 (3.6%) 7 (2.3%) MODERATE 0 2 (2.4%) 2 (2.4%) 4 (1.3%) SEVERE 0 0 0 0 DYSPHONIA     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 DYSPNOEA     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 1 (1.2%) 0 1 (1.2%) 2 (0.7%) SEVERE 0 0 0 0 EMPHYSEMA     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 EPISTAXIS     MILD 0 2 (2.4%) 1 (1.2%) 3 (1.0%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 HAEMOPTYSIS     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 NASAL CONGESTION     MILD 3 (3.5%) 3 (3.6%) 1 (1.2%) 7 (2.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 PHARYNGEAL ERYTHEMA     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 PHARYNGOLARYNGEAL PAIN     MILD 0 1 (1.2%) 1 (1.2%) 2 (0.7%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 POSTNASAL DRIP     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 PRODUCTIVE COUGH     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 RALES     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 RESPIRATORY TRACT CONGESTION     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 RHINORRHOEA     MILD 0 1 (1.2%) 1 (1.2%) 2 (0.7%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 SKIN SUBCUTANEOUS TISSUE DISORDERS     ACTINIC KERATOSIS     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 ALOPECIA     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 BLISTER     MILD 0 1 (1.2%) 1 (1.2%) 2 (0.7%) MODERATE 0 0 3 (3.6%) 3 (1.0%) SEVERE 0 0 1 (1.2%) 1 (0.3%) COLD SWEAT     MILD 0 0 0 0 MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 DERMATITIS CONTACT     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 DRUG ERUPTION     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 ERYTHEMA     MILD 4 (4.7%) 10 (11.9%) 6 (7.1%) 20 (6.5%) MODERATE 4 (4.7%) 4 (4.8%) 8 (9.5%) 16 (5.2%) SEVERE 0 0 0 0 HYPERHIDROSIS     MILD 2 (2.3%) 8 (9.5%) 1 (1.2%) 11 (3.6%) MODERATE 0 0 3 (3.6%) 3 (1.0%) SEVERE 0 0 0 0 PRURITUS     MILD 7 (8.1%) 16 (19.0%) 9 (10.7%) 32 (10.5%) MODERATE 1 (1.2%) 9 (10.7%) 11 (13.1%) 21 (6.9%) SEVERE 0 0 1 (1.2%) 1 (0.3%) PRURITUS GENERALISED     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 RASH     MILD 2 (2.3%) 5 (6.0%) 9 (10.7%) 16 (5.2%) MODERATE 3 (3.5%) 2 (2.4%) 3 (3.6%) 8 (2.6%) SEVERE 0 1 (1.2%) 1 (1.2%) 2 (0.7%) RASH ERYTHEMATOUS     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 RASH MACULO-PAPULAR     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 RASH PRURITIC     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 1 (1.2%) 1 (1.2%) 2 (0.7%) SEVERE 0 0 0 0 SKIN EXFOLIATION     MILD 0 0 0 0 MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 SKIN IRRITATION     MILD 2 (2.3%) 3 (3.6%) 2 (2.4%) 7 (2.3%) MODERATE 1 (1.2%) 2 (2.4%) 3 (3.6%) 6 (2.0%) SEVERE 0 0 1 (1.2%) 1 (0.3%) SKIN ODOUR ABNORMAL     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 SKIN ULCER     MILD 0 0 0 0 MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 URTICARIA     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 1 (1.2%) 1 (0.3%) SEVERE 0 0 0 0 SOCIAL CIRCUMSTANCES     ALCOHOL USE     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 SURGICAL MEDICAL PROCEDURES     ACROCHORDON EXCISION     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 CATARACT OPERATION     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 EYE LASER SURGERY     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 SKIN LESION EXCISION     MILD 0 1 (1.2%) 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 VASCULAR DISORDERS     HOT FLUSH     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 HYPERTENSION     MILD 0 0 1 (1.2%) 1 (0.3%) MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 HYPOTENSION     MILD 1 (1.2%) 0 1 (1.2%) 2 (0.7%) MODERATE 1 (1.2%) 0 0 1 (0.3%) SEVERE 0 0 0 0 ORTHOSTATIC HYPOTENSION     MILD 1 (1.2%) 0 0 1 (0.3%) MODERATE 0 0 0 0 SEVERE 0 0 0 0 WOUND HAEMORRHAGE     MILD 0 0 0 0 MODERATE 0 1 (1.2%) 0 1 (0.3%) SEVERE 0 0 0 0","code":"suppressMessages(library(rtables, quietly = TRUE))  adsl <- pharmaverseadam::adsl |> drop_missing_cols() adae <- pharmaverseadam::adae |> drop_missing_cols()  lyt <- build_adae_by_sev_tox(   adae = adae,   colsby = \"ARM\",   grade_val = \"AESEV\",   class_val = \"AESOC\",   term_val = \"AEDECOD\" )  tbl <- build_table(lyt = lyt$lyt, df = lyt$df_out, alt_counts_df = adsl)  # \\dontrun{ tt_to_flextable(tbl) .cl-7c3a6c2c{table-layout:auto;}.cl-7be38c36{font-family:'Arial';font-size:9pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-7be38c37{font-family:'Arial';font-size:9pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-7bfdd4c4{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-7bfdd4c5{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:3pt;padding-top:0;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-7bfdd4c6{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:0.3pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-7bfdd4c7{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-7bfdd4c8{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:23pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-7bfdd4c9{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:34.3pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-7bfdd4ca{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:45.6pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-7bff0df8{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bff0df9{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bff0dfa{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bff0dfb{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bff0dfc{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bff0dfd{background-color:transparent;vertical-align: middle;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bff0dfe{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bff0dff{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bff0e00{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bff0e01{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bff0e02{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bffa9f2{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bffa9f3{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bffa9f4{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bffa9f5{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bffa9f6{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bffa9f7{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bffa9f8{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bffa9f9{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bffa9fa{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bffa9fb{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7bffa9fc{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00460a{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00460b{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00460c{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00460d{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00460e{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00460f{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c004610{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c004611{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c004612{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c004613{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c004614{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00e25e{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00e25f{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00e260{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00e261{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00e262{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00e263{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00e264{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00e265{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00e266{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00e267{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c00e268{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c017f98{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c017f99{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c017f9a{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c017f9b{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c017f9c{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c017f9d{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c017f9e{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c017f9f{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c017fa0{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c017fa1{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c017fa2{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c021b10{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c021b11{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c021b12{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c021b13{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c021b14{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c021b15{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c021b16{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c021b17{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c021b18{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7c021b19{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}Primary System Organ Class  Dictionary-Derived TermPlacebo (N=86)Xanomeline High Dose (N=84)Xanomeline Low Dose (N=84)All Patients (N=306)Total number of patients with at least one adverse event65 (75.6%)75 (89.3%)77 (91.7%)217 (70.9%)Total number of adverse events2814294121122    CARDIAC DISORDERS      ATRIAL FIBRILLATION        MILD02 (2.4%)02 (0.7%)        MODERATE1 (1.2%)01 (1.2%)2 (0.7%)        SEVERE01 (1.2%)01 (0.3%)      ATRIAL FLUTTER        MILD01 (1.2%)01 (0.3%)        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      ATRIAL HYPERTROPHY        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      ATRIOVENTRICULAR BLOCK FIRST DEGREE        MILD1 (1.2%)01 (1.2%)2 (0.7%)        MODERATE0000        SEVERE0000      ATRIOVENTRICULAR BLOCK SECOND DEGREE        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      BRADYCARDIA        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      BUNDLE BRANCH BLOCK LEFT        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      BUNDLE BRANCH BLOCK RIGHT        MILD1 (1.2%)001 (0.3%)        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      CARDIAC DISORDER        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      CARDIAC FAILURE CONGESTIVE        MILD0000        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      MYOCARDIAL INFARCTION        MILD1 (1.2%)3 (3.6%)2 (2.4%)6 (2.0%)        MODERATE1 (1.2%)1 (1.2%)02 (0.7%)        SEVERE2 (2.3%)002 (0.7%)      PALPITATIONS        MILD0000        MODERATE002 (2.4%)2 (0.7%)        SEVERE0000      SINUS ARRHYTHMIA        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      SINUS BRADYCARDIA        MILD1 (1.2%)4 (4.8%)6 (7.1%)11 (3.6%)        MODERATE1 (1.2%)4 (4.8%)1 (1.2%)6 (2.0%)        SEVERE0000      SUPRAVENTRICULAR EXTRASYSTOLES        MILD1 (1.2%)1 (1.2%)1 (1.2%)3 (1.0%)        MODERATE0000        SEVERE0000      SUPRAVENTRICULAR TACHYCARDIA        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      TACHYCARDIA        MILD0000        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      VENTRICULAR EXTRASYSTOLES        MILD01 (1.2%)1 (1.2%)2 (0.7%)        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      VENTRICULAR HYPERTROPHY        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      WOLFF-PARKINSON-WHITE SYNDROME        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000    CONGENITAL, FAMILIAL AND GENETIC DISORDERS      VENTRICULAR SEPTAL DEFECT        MILD02 (2.4%)02 (0.7%)        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000    EAR AND LABYRINTH DISORDERS      CERUMEN IMPACTION        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000      EAR PAIN        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      VERTIGO        MILD0000        MODERATE01 (1.2%)1 (1.2%)2 (0.7%)        SEVERE0000    EYE DISORDERS      CONJUNCTIVAL HAEMORRHAGE        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      CONJUNCTIVITIS        MILD0000        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      EYE ALLERGY        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      EYE PRURITUS        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      EYE SWELLING        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      VISION BLURRED        MILD001 (1.2%)1 (0.3%)        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000    GASTROINTESTINAL DISORDERS      ABDOMINAL DISCOMFORT        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      ABDOMINAL PAIN        MILD1 (1.2%)02 (2.4%)3 (1.0%)        MODERATE01 (1.2%)1 (1.2%)2 (0.7%)        SEVERE0000      CONSTIPATION        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      DIARRHOEA        MILD9 (10.5%)2 (2.4%)4 (4.8%)15 (4.9%)        MODERATE02 (2.4%)02 (0.7%)        SEVERE0000      DYSPEPSIA        MILD1 (1.2%)001 (0.3%)        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      DYSPHAGIA        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      FLATULENCE        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      GASTROINTESTINAL HAEMORRHAGE        MILD0000        MODERATE0000        SEVERE01 (1.2%)01 (0.3%)      GASTROOESOPHAGEAL REFLUX DISEASE        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      GLOSSITIS        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      HIATUS HERNIA        MILD0000        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      NAUSEA        MILD2 (2.3%)5 (6.0%)2 (2.4%)9 (2.9%)        MODERATE1 (1.2%)01 (1.2%)2 (0.7%)        SEVERE01 (1.2%)01 (0.3%)      RECTAL HAEMORRHAGE        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000      SALIVARY HYPERSECRETION        MILD04 (4.8%)04 (1.3%)        MODERATE0000        SEVERE0000      STOMACH DISCOMFORT        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      VOMITING        MILD2 (2.3%)5 (6.0%)2 (2.4%)9 (2.9%)        MODERATE1 (1.2%)2 (2.4%)1 (1.2%)4 (1.3%)        SEVERE0000    GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS      APPLICATION SITE BLEEDING        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      APPLICATION SITE DERMATITIS        MILD5 (5.8%)2 (2.4%)4 (4.8%)11 (3.6%)        MODERATE05 (6.0%)4 (4.8%)9 (2.9%)        SEVERE001 (1.2%)1 (0.3%)      APPLICATION SITE DESQUAMATION        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000      APPLICATION SITE DISCHARGE        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      APPLICATION SITE DISCOLOURATION        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      APPLICATION SITE ERYTHEMA        MILD3 (3.5%)9 (10.7%)4 (4.8%)16 (5.2%)        MODERATE06 (7.1%)6 (7.1%)12 (3.9%)        SEVERE002 (2.4%)2 (0.7%)      APPLICATION SITE INDURATION        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      APPLICATION SITE IRRITATION        MILD1 (1.2%)3 (3.6%)3 (3.6%)7 (2.3%)        MODERATE2 (2.3%)6 (7.1%)3 (3.6%)11 (3.6%)        SEVERE003 (3.6%)3 (1.0%)      APPLICATION SITE PAIN        MILD01 (1.2%)01 (0.3%)        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      APPLICATION SITE PERSPIRATION        MILD01 (1.2%)01 (0.3%)        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      APPLICATION SITE PRURITUS        MILD5 (5.8%)10 (11.9%)13 (15.5%)28 (9.2%)        MODERATE1 (1.2%)12 (14.3%)8 (9.5%)21 (6.9%)        SEVERE001 (1.2%)1 (0.3%)      APPLICATION SITE REACTION        MILD0000        MODERATE1 (1.2%)1 (1.2%)02 (0.7%)        SEVERE0000      APPLICATION SITE SWELLING        MILD01 (1.2%)1 (1.2%)2 (0.7%)        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      APPLICATION SITE URTICARIA        MILD002 (2.4%)2 (0.7%)        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      APPLICATION SITE VESICLES        MILD1 (1.2%)2 (2.4%)3 (3.6%)6 (2.0%)        MODERATE04 (4.8%)1 (1.2%)5 (1.6%)        SEVERE0000      APPLICATION SITE WARMTH        MILD0000        MODERATE0000        SEVERE001 (1.2%)1 (0.3%)      ASTHENIA        MILD0000        MODERATE1 (1.2%)1 (1.2%)02 (0.7%)        SEVERE0000      CHEST DISCOMFORT        MILD02 (2.4%)02 (0.7%)        MODERATE0000        SEVERE0000      CHEST PAIN        MILD02 (2.4%)02 (0.7%)        MODERATE0000        SEVERE0000      CHILLS        MILD01 (1.2%)1 (1.2%)2 (0.7%)        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      FATIGUE        MILD1 (1.2%)5 (6.0%)3 (3.6%)9 (2.9%)        MODERATE002 (2.4%)2 (0.7%)        SEVERE0000      FEELING ABNORMAL        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      FEELING COLD        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      INFLAMMATION        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      MALAISE        MILD01 (1.2%)1 (1.2%)2 (0.7%)        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      OEDEMA        MILD002 (2.4%)2 (0.7%)        MODERATE0000        SEVERE0000      OEDEMA PERIPHERAL        MILD2 (2.3%)1 (1.2%)03 (1.0%)        MODERATE01 (1.2%)1 (1.2%)2 (0.7%)        SEVERE0000      PAIN        MILD01 (1.2%)01 (0.3%)        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      PYREXIA        MILD2 (2.3%)1 (1.2%)03 (1.0%)        MODERATE0000        SEVERE0000      SECRETION DISCHARGE        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000      SUDDEN DEATH        MILD0000        MODERATE0000        SEVERE001 (1.2%)1 (0.3%)      SWELLING        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      ULCER        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000    HEPATOBILIARY DISORDERS      HYPERBILIRUBINAEMIA        MILD0000        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000    IMMUNE SYSTEM DISORDERS      HYPERSENSITIVITY        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000    INFECTIONS AND INFESTATIONS      BRONCHITIS        MILD0000        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      CELLULITIS        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      CERVICITIS        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      CYSTITIS        MILD1 (1.2%)1 (1.2%)02 (0.7%)        MODERATE0000        SEVERE0000      EAR INFECTION        MILD2 (2.3%)002 (0.7%)        MODERATE0000        SEVERE0000      GASTROENTERITIS VIRAL        MILD0000        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      HORDEOLUM        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      INFLUENZA        MILD1 (1.2%)1 (1.2%)1 (1.2%)3 (1.0%)        MODERATE0000        SEVERE0000      LOCALISED INFECTION        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      LOWER RESPIRATORY TRACT INFECTION        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      NASOPHARYNGITIS        MILD1 (1.2%)5 (6.0%)3 (3.6%)9 (2.9%)        MODERATE1 (1.2%)1 (1.2%)02 (0.7%)        SEVERE001 (1.2%)1 (0.3%)      PNEUMONIA        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      RHINITIS        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      UPPER RESPIRATORY TRACT INFECTION        MILD4 (4.7%)2 (2.4%)1 (1.2%)7 (2.3%)        MODERATE2 (2.3%)1 (1.2%)03 (1.0%)        SEVERE0000      URINARY TRACT INFECTION        MILD2 (2.3%)1 (1.2%)03 (1.0%)        MODERATE0000        SEVERE0000      VAGINAL MYCOSIS        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      VIRAL INFECTION        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000    INJURY, POISONING AND PROCEDURAL COMPLICATIONS      CONTUSION        MILD1 (1.2%)2 (2.4%)03 (1.0%)        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      EXCORIATION        MILD2 (2.3%)002 (0.7%)        MODERATE01 (1.2%)1 (1.2%)2 (0.7%)        SEVERE0000      FACIAL BONES FRACTURE        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      FALL        MILD1 (1.2%)1 (1.2%)1 (1.2%)3 (1.0%)        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      HIP FRACTURE        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE1 (1.2%)1 (1.2%)02 (0.7%)      JOINT DISLOCATION        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      SKIN LACERATION        MILD1 (1.2%)01 (1.2%)2 (0.7%)        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      WOUND        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000    INVESTIGATIONS      BIOPSY        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      BIOPSY PROSTATE        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      BLOOD ALKALINE PHOSPHATASE INCREASED        MILD0000        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      BLOOD CHOLESTEROL INCREASED        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      BLOOD CREATINE PHOSPHOKINASE INCREASED        MILD0000        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      BLOOD GLUCOSE INCREASED        MILD01 (1.2%)1 (1.2%)2 (0.7%)        MODERATE0000        SEVERE0000      BLOOD URINE PRESENT        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      BODY TEMPERATURE INCREASED        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000      CYSTOSCOPY        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      ELECTROCARDIOGRAM ST SEGMENT DEPRESSION        MILD4 (4.7%)01 (1.2%)5 (1.6%)        MODERATE0000        SEVERE0000      ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED        MILD1 (1.2%)01 (1.2%)2 (0.7%)        MODERATE0000        SEVERE0000      ELECTROCARDIOGRAM T WAVE INVERSION        MILD2 (2.3%)1 (1.2%)1 (1.2%)4 (1.3%)        MODERATE0000        SEVERE0000      HEART RATE INCREASED        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      HEART RATE IRREGULAR        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      NASAL MUCOSA BIOPSY        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000      WEIGHT DECREASED        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000    METABOLISM AND NUTRITION DISORDERS      DECREASED APPETITE        MILD0000        MODERATE1 (1.2%)1 (1.2%)02 (0.7%)        SEVERE0000      DEHYDRATION        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      DIABETES MELLITUS        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      FOOD CRAVING        MILD1 (1.2%)001 (0.3%)        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      HYPONATRAEMIA        MILD0000        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      INCREASED APPETITE        MILD1 (1.2%)1 (1.2%)02 (0.7%)        MODERATE0000        SEVERE0000    MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS      ARTHRALGIA        MILD1 (1.2%)001 (0.3%)        MODERATE01 (1.2%)2 (2.4%)3 (1.0%)        SEVERE0000      ARTHRITIS        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      BACK PAIN        MILD1 (1.2%)2 (2.4%)03 (1.0%)        MODERATE01 (1.2%)1 (1.2%)2 (0.7%)        SEVERE0000      FLANK PAIN        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      MUSCLE SPASMS        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE001 (1.2%)1 (0.3%)      MUSCULAR WEAKNESS        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      MYALGIA        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      PAIN IN EXTREMITY        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      SHOULDER PAIN        MILD002 (2.4%)2 (0.7%)        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000    NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)      COLON CANCER        MILD0000        MODERATE0000        SEVERE001 (1.2%)1 (0.3%)      MALIGNANT FIBROUS HISTIOCYTOMA        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000      PROSTATE CANCER        MILD0000        MODERATE0000        SEVERE01 (1.2%)01 (0.3%)    NERVOUS SYSTEM DISORDERS      AMNESIA        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      BALANCE DISORDER        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      BURNING SENSATION        MILD01 (1.2%)01 (0.3%)        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      COGNITIVE DISORDER        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      COMPLEX PARTIAL SEIZURES        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      COORDINATION ABNORMAL        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000      DIZZINESS        MILD2 (2.3%)7 (8.3%)5 (6.0%)14 (4.6%)        MODERATE03 (3.6%)3 (3.6%)6 (2.0%)        SEVERE01 (1.2%)01 (0.3%)      HEADACHE        MILD3 (3.5%)4 (4.8%)2 (2.4%)9 (2.9%)        MODERATE01 (1.2%)01 (0.3%)        SEVERE001 (1.2%)1 (0.3%)      HEMIANOPIA HOMONYMOUS        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000      HYPERSOMNIA        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      LETHARGY        MILD0000        MODERATE01 (1.2%)1 (1.2%)2 (0.7%)        SEVERE0000      PARAESTHESIA        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      PARAESTHESIA ORAL        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000      PARKINSON'S DISEASE        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      PAROSMIA        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      PARTIAL SEIZURES WITH SECONDARY GENERALISATION        MILD0000        MODERATE0000        SEVERE01 (1.2%)01 (0.3%)      PSYCHOMOTOR HYPERACTIVITY        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      SOMNOLENCE        MILD01 (1.2%)1 (1.2%)2 (0.7%)        MODERATE2 (2.3%)02 (2.4%)4 (1.3%)        SEVERE0000      STUPOR        MILD0000        MODERATE0000        SEVERE001 (1.2%)1 (0.3%)      SYNCOPE        MILD001 (1.2%)1 (0.3%)        MODERATE02 (2.4%)1 (1.2%)3 (1.0%)        SEVERE01 (1.2%)2 (2.4%)3 (1.0%)      SYNCOPE VASOVAGAL        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      TRANSIENT ISCHAEMIC ATTACK        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE01 (1.2%)1 (1.2%)2 (0.7%)    PSYCHIATRIC DISORDERS      AGITATION        MILD2 (2.3%)002 (0.7%)        MODERATE01 (1.2%)1 (1.2%)2 (0.7%)        SEVERE001 (1.2%)1 (0.3%)      ANXIETY        MILD003 (3.6%)3 (1.0%)        MODERATE0000        SEVERE0000      COMPLETED SUICIDE        MILD0000        MODERATE0000        SEVERE1 (1.2%)001 (0.3%)      CONFUSIONAL STATE        MILD1 (1.2%)1 (1.2%)02 (0.7%)        MODERATE1 (1.2%)03 (3.6%)4 (1.3%)        SEVERE0000      DELIRIUM        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      DELUSION        MILD1 (1.2%)001 (0.3%)        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      DEPRESSED MOOD        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      DISORIENTATION        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      HALLUCINATION        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      HALLUCINATION, VISUAL        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      INSOMNIA        MILD2 (2.3%)2 (2.4%)04 (1.3%)        MODERATE0000        SEVERE0000      IRRITABILITY        MILD001 (1.2%)1 (0.3%)        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      LIBIDO DECREASED        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      LISTLESS        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      NIGHTMARE        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      RESTLESSNESS        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000    RENAL AND URINARY DISORDERS      CALCULUS URETHRAL        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000      DYSURIA        MILD1 (1.2%)01 (1.2%)2 (0.7%)        MODERATE0000        SEVERE0000      INCONTINENCE        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000      MICTURITION URGENCY        MILD1 (1.2%)1 (1.2%)1 (1.2%)3 (1.0%)        MODERATE0000        SEVERE0000      NEPHROLITHIASIS        MILD0000        MODERATE1 (1.2%)1 (1.2%)02 (0.7%)        SEVERE0000      POLLAKIURIA        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000    REPRODUCTIVE SYSTEM AND BREAST DISORDERS      BENIGN PROSTATIC HYPERPLASIA        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE1 (1.2%)001 (0.3%)      PELVIC PAIN        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000    RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS      ALLERGIC GRANULOMATOUS ANGIITIS        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      COUGH        MILD1 (1.2%)3 (3.6%)3 (3.6%)7 (2.3%)        MODERATE02 (2.4%)2 (2.4%)4 (1.3%)        SEVERE0000      DYSPHONIA        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000      DYSPNOEA        MILD01 (1.2%)01 (0.3%)        MODERATE1 (1.2%)01 (1.2%)2 (0.7%)        SEVERE0000      EMPHYSEMA        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      EPISTAXIS        MILD02 (2.4%)1 (1.2%)3 (1.0%)        MODERATE0000        SEVERE0000      HAEMOPTYSIS        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      NASAL CONGESTION        MILD3 (3.5%)3 (3.6%)1 (1.2%)7 (2.3%)        MODERATE0000        SEVERE0000      PHARYNGEAL ERYTHEMA        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      PHARYNGOLARYNGEAL PAIN        MILD01 (1.2%)1 (1.2%)2 (0.7%)        MODERATE0000        SEVERE0000      POSTNASAL DRIP        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      PRODUCTIVE COUGH        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      RALES        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      RESPIRATORY TRACT CONGESTION        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      RHINORRHOEA        MILD01 (1.2%)1 (1.2%)2 (0.7%)        MODERATE0000        SEVERE0000    SKIN AND SUBCUTANEOUS TISSUE DISORDERS      ACTINIC KERATOSIS        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      ALOPECIA        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      BLISTER        MILD01 (1.2%)1 (1.2%)2 (0.7%)        MODERATE003 (3.6%)3 (1.0%)        SEVERE001 (1.2%)1 (0.3%)      COLD SWEAT        MILD0000        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      DERMATITIS CONTACT        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      DRUG ERUPTION        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      ERYTHEMA        MILD4 (4.7%)10 (11.9%)6 (7.1%)20 (6.5%)        MODERATE4 (4.7%)4 (4.8%)8 (9.5%)16 (5.2%)        SEVERE0000      HYPERHIDROSIS        MILD2 (2.3%)8 (9.5%)1 (1.2%)11 (3.6%)        MODERATE003 (3.6%)3 (1.0%)        SEVERE0000      PRURITUS        MILD7 (8.1%)16 (19.0%)9 (10.7%)32 (10.5%)        MODERATE1 (1.2%)9 (10.7%)11 (13.1%)21 (6.9%)        SEVERE001 (1.2%)1 (0.3%)      PRURITUS GENERALISED        MILD01 (1.2%)01 (0.3%)        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      RASH        MILD2 (2.3%)5 (6.0%)9 (10.7%)16 (5.2%)        MODERATE3 (3.5%)2 (2.4%)3 (3.6%)8 (2.6%)        SEVERE01 (1.2%)1 (1.2%)2 (0.7%)      RASH ERYTHEMATOUS        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      RASH MACULO-PAPULAR        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      RASH PRURITIC        MILD01 (1.2%)01 (0.3%)        MODERATE01 (1.2%)1 (1.2%)2 (0.7%)        SEVERE0000      SKIN EXFOLIATION        MILD0000        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000      SKIN IRRITATION        MILD2 (2.3%)3 (3.6%)2 (2.4%)7 (2.3%)        MODERATE1 (1.2%)2 (2.4%)3 (3.6%)6 (2.0%)        SEVERE001 (1.2%)1 (0.3%)      SKIN ODOUR ABNORMAL        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      SKIN ULCER        MILD0000        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      URTICARIA        MILD01 (1.2%)01 (0.3%)        MODERATE001 (1.2%)1 (0.3%)        SEVERE0000    SOCIAL CIRCUMSTANCES      ALCOHOL USE        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000    SURGICAL AND MEDICAL PROCEDURES      ACROCHORDON EXCISION        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000      CATARACT OPERATION        MILD001 (1.2%)1 (0.3%)        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      EYE LASER SURGERY        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      SKIN LESION EXCISION        MILD01 (1.2%)01 (0.3%)        MODERATE0000        SEVERE0000    VASCULAR DISORDERS      HOT FLUSH        MILD001 (1.2%)1 (0.3%)        MODERATE0000        SEVERE0000      HYPERTENSION        MILD001 (1.2%)1 (0.3%)        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      HYPOTENSION        MILD1 (1.2%)01 (1.2%)2 (0.7%)        MODERATE1 (1.2%)001 (0.3%)        SEVERE0000      ORTHOSTATIC HYPOTENSION        MILD1 (1.2%)001 (0.3%)        MODERATE0000        SEVERE0000      WOUND HAEMORRHAGE        MILD0000        MODERATE01 (1.2%)01 (0.3%)        SEVERE0000# }"},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_summary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Create ADAE Summary Table — build_adae_summary","text":"","code":"build_adae_summary(adae, filter_cond = NULL, event_vars, trt_var)"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_summary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Create ADAE Summary Table — build_adae_summary","text":"adae (data.frame) ADAE dataset. filter_cond (character) Filtering condition required adae. event_vars (vector character) Variables added source ADAE add_adae_flags(). trt_var (character) Arm variable used split table columns.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_summary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Create ADAE Summary Table — build_adae_summary","text":"List containing layout object ADAE Summary Table filtered ADAE data","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_summary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Create ADAE Summary Table — build_adae_summary","text":"Adverse Events Placebo (N=86) Xanomeline High Dose (N=84) Xanomeline Low Dose (N=84) Patients (N=306) Serious AE 0 2 (2.4%) 1 (1.2%) 3 (1.0%) SAEs fatal outcome 0 0 0 0 Life-threatening SAEs 0 1 (1.2%) 0 1 (0.3%) SAEs requiring hospitalization 0 1 (1.2%) 1 (1.2%) 2 (0.7%) SAEs resulting substantial disruption normal life functions 0 0 0 0 Congenital anomaly birth defect 0 0 0 0 SAEs 0 0 0 0 AE leading permanent discontinuation study drug 0 0 0 0 AE leading dose modification/interruption 0 0 0 0 AE leading interruption study drug 0 0 0 0 AE leading reduction study drug 0 0 0 0 AE leading dose delay study drug 0 0 0 0 AEs 0 0 0 0 AE 65 (75.6%) 75 (89.3%) 77 (91.7%) 217 (70.9%) MILD 36 (41.9%) 22 (26.2%) 19 (22.6%) 77 (25.2%) MODERATE 24 (27.9%) 45 (53.6%) 42 (50.0%) 111 (36.3%) SEVERE 5 (5.8%) 8 (9.5%) 16 (19.0%) 29 (9.5%) Grade 3-5 AE 0 0 0 0 Grade 4/5 AE 0 0 0 0","code":"suppressMessages(library(rtables))  adsl <- pharmaverseadam::adsl |> drop_missing_cols() adae <- pharmaverseadam::adae |> drop_missing_cols()  adae_ <- suppressMessages(add_adae_flags(adae)) lyt <- build_adae_summary(   adae = adae_,   filter_cond = NULL,   event_vars = setdiff(names(adae_), names(adae)),   trt_var = \"ARM\" ) tbl <- build_table(lyt = lyt$lyt, df = lyt$df_out, alt_counts_df = adsl)  # \\dontrun{ tt_to_flextable(tbl) .cl-8004e01c{table-layout:auto;}.cl-7ff5af8e{font-family:'Arial';font-size:9pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-7ff5af8f{font-family:'Arial';font-size:9pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-7ffbca2c{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-7ffbca2d{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:3pt;padding-top:0;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-7ffbca2e{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:11.6pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-7ffbca2f{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-7ffbca30{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:23pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-7ffbca31{background-color:transparent;vertical-align: middle;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffbca32{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffbca33{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffbca34{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffbca35{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffbca36{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffc664e{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffc664f{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffc6650{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffc6651{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffc6652{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffc6653{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffc6654{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffc6655{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffc6656{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffc6657{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffc6658{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffd0270{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffd0271{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffd0272{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffd0273{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffd0274{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffd0275{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffd0276{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-7ffd0277{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}Adverse EventsPlacebo (N=86)Xanomeline High Dose (N=84)Xanomeline Low Dose (N=84)All Patients (N=306)  Serious AE02 (2.4%)1 (1.2%)3 (1.0%)    SAEs with fatal outcome0000    Life-threatening SAEs01 (1.2%)01 (0.3%)    SAEs requiring hospitalization01 (1.2%)1 (1.2%)2 (0.7%)    SAEs resulting in substantial disruption of normal life functions0000    Congenital anomaly or birth defect0000    Other SAEs0000  AE leading to permanent discontinuation of study drug0000  AE leading to dose modification/interruption0000    AE leading to interruption of study drug0000    AE leading to reduction of study drug0000    AE leading to dose delay of study drug0000    Other AEs0000  Any AE65 (75.6%)75 (89.3%)77 (91.7%)217 (70.9%)    MILD36 (41.9%)22 (26.2%)19 (22.6%)77 (25.2%)    MODERATE24 (27.9%)45 (53.6%)42 (50.0%)111 (36.3%)    SEVERE5 (5.8%)8 (9.5%)16 (19.0%)29 (9.5%)    Grade 3-5 AE0000    Grade 4/5 AE0000# }"},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl_chars_table.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Baseline Demographic and Clinical Characteristics — build_adsl_chars_table","text":"","code":"build_adsl_chars_table(   title = \"\",   subtitle = character(),   footer = character(),   split_cols_by = \"ARM\",   summ_vars = c(\"AGE\", \"SEX\", \"COUNTRY\"),   disp_stat = c(\"n\", \"mean_sd\", \"se\", \"median\", \"range\", \"quantiles\", \"count_fraction\") )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl_chars_table.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Baseline Demographic and Clinical Characteristics — build_adsl_chars_table","text":"title (character) Title demographic table. subtitle (character) Subtitle demographic table. footer (character) Footer demographic table. split_cols_by (character) Arm variable used split table columns. summ_vars (vector character) Variables df include table. disp_stat (vector character) Statistics display.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl_chars_table.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Baseline Demographic and Clinical Characteristics — build_adsl_chars_table","text":"tabletree object.","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl_chars_table.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Baseline Demographic and Clinical Characteristics — build_adsl_chars_table","text":"Characteristic Placebo (N=86) Screen Failure (N=52) Xanomeline High Dose (N=84) Xanomeline Low Dose (N=84) Patients (N=306) AGE      n 86 52 84 84 306 Mean, SD 75.2 (8.6) 75.1 (9.7) 74.4 (7.9) 75.7 (8.3) 75.1 (8.5) Standard Error 0.9 1.3 0.9 0.9 0.5 Median 76.0 76.0 76.0 77.5 77.0 Min-Max 52.0 - 89.0 50.0 - 89.0 56.0 - 88.0 51.0 - 88.0 50.0 - 89.0 IQR 69.0 - 82.0 71.5 - 81.5 70.5 - 80.0 71.0 - 82.0 70.0 - 81.0 RACE      n 86 52 84 84 306 AMERICAN INDIAN ALASKA NATIVE 0 1 (1.9%) 1 (1.2%) 0 2 (0.7%) ASIAN 0 2 (3.8%) 0 0 2 (0.7%) BLACK AFRICAN AMERICAN 8 (9.3%) 6 (11.5%) 9 (10.7%) 6 (7.1%) 29 (9.5%) WHITE 78 (90.7%) 43 (82.7%) 74 (88.1%) 78 (92.9%) 273 (89.2%)","code":"adsl <- pharmaverseadam::adsl |> drop_missing_cols()  lyt <- build_adsl_chars_table(   split_cols_by = \"ARM\",   summ_vars = c(\"AGE\", \"RACE\") ) tbl <- rtables::build_table(lyt, adsl)  # \\dontrun{ tt_to_flextable(tbl) .cl-81a1db8c{table-layout:auto;}.cl-8194d6d0{font-family:'Arial';font-size:9pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-8194d6d1{font-family:'Arial';font-size:9pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-81995fac{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-81995fad{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:3pt;padding-top:0;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-81995fae{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:0.3pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-81995faf{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-81995fb0{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:11.6pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-81998ba8{background-color:transparent;vertical-align: middle;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-81998ba9{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-81998baa{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-81998bab{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-81998bac{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-81998bad{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-81998bae{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-81998baf{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-81998bb0{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-81998bb1{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-81998bb2{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b6aa{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b6ab{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b6ac{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b6ad{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b6ae{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b6af{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b6b0{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b6b1{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b6b2{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b6b3{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b6b4{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b718{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b719{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b71a{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b71b{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b71c{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b71d{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b71e{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b71f{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b720{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b721{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199b722{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199e1c0{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199e1c1{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199e1c2{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199e1c3{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199e1c4{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199e1c5{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199e1c6{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199e1c7{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8199e1c8{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}CharacteristicPlacebo (N=86)Screen Failure (N=52)Xanomeline High Dose (N=84)Xanomeline Low Dose (N=84)All Patients (N=306)AGE  n86528484306  Mean, SD75.2 (8.6)75.1 (9.7)74.4 (7.9)75.7 (8.3)75.1 (8.5)  Standard Error0.91.30.90.90.5  Median76.076.076.077.577.0  Min-Max52.0 - 89.050.0 - 89.056.0 - 88.051.0 - 88.050.0 - 89.0  IQR69.0 - 82.071.5 - 81.570.5 - 80.071.0 - 82.070.0 - 81.0RACE  n86528484306  AMERICAN INDIAN OR ALASKA NATIVE01 (1.9%)1 (1.2%)02 (0.7%)  ASIAN02 (3.8%)002 (0.7%)  BLACK OR AFRICAN AMERICAN8 (9.3%)6 (11.5%)9 (10.7%)6 (7.1%)29 (9.5%)  WHITE78 (90.7%)43 (82.7%)74 (88.1%)78 (92.9%)273 (89.2%)# }"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_disp_table.html","id":null,"dir":"Reference","previous_headings":"","what":"Disposition Summary Table — build_disp_table","title":"Disposition Summary Table — build_disp_table","text":"Disposition Summary Table","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_disp_table.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Disposition Summary Table — build_disp_table","text":"","code":"build_disp_table(   adsl,   trt_var,   eos_var = \"EOSSTT\",   eot_var = \"EOTSTT\",   dcs_reas = \"DCSREAS\",   dct_reas = \"DCTREAS\" )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_disp_table.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Disposition Summary Table — build_disp_table","text":"adsl (data.frame) adsl data set. trt_var (character) Arm variable used split table columns. eos_var (character) Name end study variable, default \"EOSSTT\". eot_var (character) Name end treatment variable, default \"EOTSTT\". dcs_reas (character) Name study discontinuation reason variable, default \"DCSREAS\". dct_reas (character) Name treatment discontinuation reason variable, default \"DCTREAS\".","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_disp_table.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Disposition Summary Table — build_disp_table","text":"rtable object Disposition Summary Table","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_disp_table.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Disposition Summary Table — build_disp_table","text":"Placebo (N=86) Screen Failure (N=52) Xanomeline High Dose (N=84) Xanomeline Low Dose (N=84) Patients (N=306) Safety Population 86 (100.0%) 0 (0.0%) 84 (100.0%) 84 (100.0%) 254 (83.0%) Discontinued Study 28 (32.6%) 0 (0.0%) 57 (67.9%) 59 (70.2%) 144 (47.1%)","code":"library(rtables)  adsl <- pharmaverseadam::adsl |> drop_missing_cols()  tbl <- build_disp_table(   adsl = adsl,   trt_var = \"ARM\",   eos_var = \"EOSSTT\",   eot_var = \"EOTSTT\",   dcs_reas = \"DCSREAS\",   dct_reas = \"DCTREAS\" )  # \\dontrun{ tt_to_flextable(tbl) .cl-82bf8dde{table-layout:auto;}.cl-82b60430{font-family:'Arial';font-size:9pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-82b60431{font-family:'Arial';font-size:9pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-82b8fee2{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-82b8fee3{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:3pt;padding-top:0;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-82b8fee4{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:0.3pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-82b8fee5{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-82b99bcc{background-color:transparent;vertical-align: middle;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82b99bcd{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82b99bce{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82b99bcf{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82b99bd0{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82b99bd1{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82b99bd2{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82b99bd3{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82b99bd4{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82b99bd5{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82b99bd6{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82ba3726{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82ba3727{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82ba3728{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82ba3729{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82ba372a{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82ba372b{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-82ba372c{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}Placebo (N=86)Screen Failure (N=52)Xanomeline High Dose (N=84)Xanomeline Low Dose (N=84)All Patients (N=306)Safety Population86 (100.0%)0 (0.0%)84 (100.0%)84 (100.0%)254 (83.0%)Discontinued Study28 (32.6%)0 (0.0%)57 (67.9%)59 (70.2%)144 (47.1%)# }"},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_generic_bds_table.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Create generic BDS Summary table — build_generic_bds_table","text":"","code":"build_generic_bds_table(   bds_df,   filter_cond = NULL,   param,   trt_var,   visit = \"AVISIT\",   timepoint = NULL,   disp_vars )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_generic_bds_table.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Create generic BDS Summary table — build_generic_bds_table","text":"bds_df (data.frame) BDS dataset (typically ADVS, ADLB etc) filter_cond (character) Filtering condition required bds_df. param (character) BDS parameter value PARAM trt_var (character) Arm variable used split table columns. visit (character) Visit variable name eg. AVISIT timepoint (character) Timepoint variable name eg. ATPT disp_vars (vector characters) Variables summarize","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_generic_bds_table.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Create generic BDS Summary table — build_generic_bds_table","text":"List containing Generic BDS table layout filtered BDS data","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_generic_bds_table.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Create generic BDS Summary table — build_generic_bds_table","text":"Placebo Xanomeline High Dose Xanomeline Low Dose Analysis Visit       Summary Statistic Analysis Value (N=86) Change Baseline (N=86) Analysis Value (N=84) Change Baseline (N=84) Analysis Value (N=84) Change Baseline (N=84) Baseline       n 340 255 336 252 336 252 Mean (SD) 77.1 (10.7) 0.0 (0.0) 78.3 (10.0) 0.0 (0.0) 76.4 (10.0) 0.0 (0.0) Median 77.7 0.0 79.2 0.0 76.0 0.0 Min - Max 40.0 - 110.0 0.0 - 0.0 51.0 - 108.0 0.0 - 0.0 48.0 - 108.0 0.0 - 0.0 Week 2       n 336 252 325 243 335 251 Mean (SD) 74.5 (10.2) -2.7 (9.8) 76.4 (10.6) -1.7 (10.9) 76.2 (9.7) -0.2 (8.8) Median 74.0 -2.0 77.0 0.0 76.0 0.0 Min - Max 45.0 - 100.0 -34.0 - 30.0 43.0 - 118.0 -38.0 - 28.0 45.0 - 102.0 -28.0 - 32.0 Week 4       n 328 246 292 219 288 216 Mean (SD) 75.4 (11.3) -1.6 (9.8) 76.8 (9.4) -1.5 (11.1) 76.0 (9.2) -0.7 (9.3) Median 76.0 -2.0 78.0 -1.0 76.0 0.0 Min - Max 39.0 - 100.0 -28.0 - 30.0 54.0 - 100.0 -32.0 - 26.0 50.0 - 102.0 -30.0 - 28.0 Week 6       n 304 228 271 203 260 195 Mean (SD) 74.5 (10.0) -3.0 (9.6) 75.3 (9.7) -3.3 (10.1) 74.9 (9.0) -1.1 (8.6) Median 74.0 -2.0 76.0 -2.0 76.0 0.0 Min - Max 48.0 - 110.0 -28.0 - 26.0 52.0 - 98.0 -50.0 - 20.0 50.0 - 100.0 -29.0 - 34.0 Week 8       n 292 219 224 168 240 180 Mean (SD) 75.2 (9.1) -2.1 (9.0) 77.4 (9.1) -1.3 (9.7) 75.4 (10.6) -0.7 (10.7) Median 76.0 -2.0 78.3 0.0 74.0 0.0 Min - Max 49.0 - 101.0 -30.0 - 24.0 54.0 - 98.0 -45.0 - 22.0 52.0 - 100.0 -30.0 - 34.0 Week 12       n 276 207 200 150 208 156 Mean (SD) 74.3 (10.8) -2.9 (9.1) 74.6 (9.1) -4.1 (10.9) 75.7 (10.7) -1.0 (10.3) Median 73.2 -2.0 76.0 -3.5 75.0 -2.0 Min - Max 49.0 - 104.0 -26.0 - 20.0 54.0 - 92.0 -46.0 - 20.0 50.0 - 100.0 -25.0 - 34.0 Week 16       n 272 204 148 111 168 126 Mean (SD) 75.1 (10.9) -1.8 (9.6) 76.0 (9.0) -2.0 (10.9) 75.2 (10.0) -1.6 (10.2) Median 76.0 0.0 77.3 0.0 75.7 -2.0 Min - Max 49.0 - 98.0 -30.0 - 24.0 50.0 - 92.0 -38.0 - 27.0 55.0 - 98.0 -30.0 - 38.0 Week 20       n 264 198 128 96 120 90 Mean (SD) 73.4 (10.4) -3.2 (9.5) 74.1 (10.1) -2.9 (11.0) 73.7 (9.5) -3.0 (10.4) Median 72.0 -4.0 72.0 -2.0 73.2 -2.0 Min - Max 48.0 - 100.0 -27.0 - 18.0 54.0 - 98.0 -36.0 - 28.0 51.0 - 98.0 -30.0 - 20.0 Week 24       n 236 177 120 90 108 81 Mean (SD) 73.8 (11.7) -2.1 (10.3) 74.9 (10.0) -2.2 (9.9) 76.2 (9.6) -0.5 (7.8) Median 74.0 -3.0 75.5 -4.0 76.0 0.0 Min - Max 44.0 - 117.0 -28.0 - 41.0 50.0 - 98.0 -20.0 - 22.0 57.0 - 98.0 -20.0 - 18.0 Week 26       n 232 174 112 84 100 75 Mean (SD) 72.6 (10.8) -3.6 (9.8) 74.5 (10.3) -3.0 (9.8) 72.9 (9.7) -3.6 (8.1) Median 72.0 -4.0 74.3 -4.0 72.0 -2.0 Min - Max 39.0 - 98.0 -27.0 - 24.0 50.0 - 93.0 -20.0 - 20.0 56.0 - 92.0 -20.0 - 22.0 End Treatment       n 222 222 168 168 177 177 Mean (SD) 74.4 (10.7) -3.0 (9.0) 76.0 (9.9) -2.7 (11.3) 76.0 (11.2) 0.1 (10.1) Median 73.5 -2.0 78.0 -2.0 76.0 0.0 Min - Max 49.0 - 104.0 -26.0 - 20.0 56.0 - 98.0 -46.0 - 20.0 50.0 - 100.0 -25.0 - 34.0 <Missing>       n 1284 963 1215 912 1242 932 Mean (SD) 76.3 (10.4) -1.0 (9.2) 77.4 (10.1) -0.9 (9.3) 75.8 (9.5) -0.3 (9.3) Median 78.0 0.0 78.0 0.0 75.3 0.0 Min - Max 39.0 - 108.0 -28.0 - 49.0 40.0 - 110.0 -43.0 - 46.0 40.0 - 102.0 -34.0 - 32.0","code":"library(rtables) adsl <- pharmaverseadam::adsl |> drop_missing_cols() advs <- pharmaverseadam::advs |> drop_missing_cols()  lyt <- build_generic_bds_table(advs,   param = \"Diastolic Blood Pressure (mmHg)\",   trt_var = \"ARM\", visit = \"AVISIT\",   disp_vars = c(\"AVAL\", \"CHG\") ) # \\dontrun{ tt_to_flextable(build_table(lyt = lyt$lyt, df = lyt$df_out, alt_counts_df = adsl)) .cl-87e4d378{table-layout:auto;}.cl-87d935e0{font-family:'Arial';font-size:9pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-87d935e1{font-family:'Arial';font-size:9pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-87dcdf2e{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-87dcdf2f{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:3pt;padding-top:0;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-87dcdf30{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:11.6pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-87dcdf31{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-87dcdf32{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:23pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-87dcdf33{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dcdf34{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dcdf35{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dcdf36{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dcdf37{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dcdf38{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dd7ba0{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dd7ba1{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dd7ba2{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dd7ba3{background-color:transparent;vertical-align: middle;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dd7ba4{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dd7ba5{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dd7ba6{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dd7ba7{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dd7ba8{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dd7ba9{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87dd7baa{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87de17ae{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87de17af{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87de17b0{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87de17b1{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87de17b2{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87de17b3{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87de17b4{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87de17b5{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87de17b6{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87de17b7{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87de17b8{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87deb3da{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87deb3db{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87deb3dc{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87deb3dd{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87deb3de{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87deb3df{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87deb3e0{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87deb3e1{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87deb3e2{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87deb3e3{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87deb3e4{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87df501a{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87df501b{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87df501c{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87df501d{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87df501e{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-87df501f{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}PlaceboXanomeline High DoseXanomeline Low DoseAnalysis Visit  Summary StatisticAnalysis Value (N=86)Change from Baseline (N=86)Analysis Value (N=84)Change from Baseline (N=84)Analysis Value (N=84)Change from Baseline (N=84)  Baseline    n340255336252336252    Mean (SD)77.1 (10.7)0.0 (0.0)78.3 (10.0)0.0 (0.0)76.4 (10.0)0.0 (0.0)    Median77.70.079.20.076.00.0    Min - Max40.0 - 110.00.0 - 0.051.0 - 108.00.0 - 0.048.0 - 108.00.0 - 0.0  Week 2    n336252325243335251    Mean (SD)74.5 (10.2)-2.7 (9.8)76.4 (10.6)-1.7 (10.9)76.2 (9.7)-0.2 (8.8)    Median74.0-2.077.00.076.00.0    Min - Max45.0 - 100.0-34.0 - 30.043.0 - 118.0-38.0 - 28.045.0 - 102.0-28.0 - 32.0  Week 4    n328246292219288216    Mean (SD)75.4 (11.3)-1.6 (9.8)76.8 (9.4)-1.5 (11.1)76.0 (9.2)-0.7 (9.3)    Median76.0-2.078.0-1.076.00.0    Min - Max39.0 - 100.0-28.0 - 30.054.0 - 100.0-32.0 - 26.050.0 - 102.0-30.0 - 28.0  Week 6    n304228271203260195    Mean (SD)74.5 (10.0)-3.0 (9.6)75.3 (9.7)-3.3 (10.1)74.9 (9.0)-1.1 (8.6)    Median74.0-2.076.0-2.076.00.0    Min - Max48.0 - 110.0-28.0 - 26.052.0 - 98.0-50.0 - 20.050.0 - 100.0-29.0 - 34.0  Week 8    n292219224168240180    Mean (SD)75.2 (9.1)-2.1 (9.0)77.4 (9.1)-1.3 (9.7)75.4 (10.6)-0.7 (10.7)    Median76.0-2.078.30.074.00.0    Min - Max49.0 - 101.0-30.0 - 24.054.0 - 98.0-45.0 - 22.052.0 - 100.0-30.0 - 34.0  Week 12    n276207200150208156    Mean (SD)74.3 (10.8)-2.9 (9.1)74.6 (9.1)-4.1 (10.9)75.7 (10.7)-1.0 (10.3)    Median73.2-2.076.0-3.575.0-2.0    Min - Max49.0 - 104.0-26.0 - 20.054.0 - 92.0-46.0 - 20.050.0 - 100.0-25.0 - 34.0  Week 16    n272204148111168126    Mean (SD)75.1 (10.9)-1.8 (9.6)76.0 (9.0)-2.0 (10.9)75.2 (10.0)-1.6 (10.2)    Median76.00.077.30.075.7-2.0    Min - Max49.0 - 98.0-30.0 - 24.050.0 - 92.0-38.0 - 27.055.0 - 98.0-30.0 - 38.0  Week 20    n2641981289612090    Mean (SD)73.4 (10.4)-3.2 (9.5)74.1 (10.1)-2.9 (11.0)73.7 (9.5)-3.0 (10.4)    Median72.0-4.072.0-2.073.2-2.0    Min - Max48.0 - 100.0-27.0 - 18.054.0 - 98.0-36.0 - 28.051.0 - 98.0-30.0 - 20.0  Week 24    n2361771209010881    Mean (SD)73.8 (11.7)-2.1 (10.3)74.9 (10.0)-2.2 (9.9)76.2 (9.6)-0.5 (7.8)    Median74.0-3.075.5-4.076.00.0    Min - Max44.0 - 117.0-28.0 - 41.050.0 - 98.0-20.0 - 22.057.0 - 98.0-20.0 - 18.0  Week 26    n2321741128410075    Mean (SD)72.6 (10.8)-3.6 (9.8)74.5 (10.3)-3.0 (9.8)72.9 (9.7)-3.6 (8.1)    Median72.0-4.074.3-4.072.0-2.0    Min - Max39.0 - 98.0-27.0 - 24.050.0 - 93.0-20.0 - 20.056.0 - 92.0-20.0 - 22.0  End of Treatment    n222222168168177177    Mean (SD)74.4 (10.7)-3.0 (9.0)76.0 (9.9)-2.7 (11.3)76.0 (11.2)0.1 (10.1)    Median73.5-2.078.0-2.076.00.0    Min - Max49.0 - 104.0-26.0 - 20.056.0 - 98.0-46.0 - 20.050.0 - 100.0-25.0 - 34.0  <Missing>    n128496312159121242932    Mean (SD)76.3 (10.4)-1.0 (9.2)77.4 (10.1)-0.9 (9.3)75.8 (9.5)-0.3 (9.3)    Median78.00.078.00.075.30.0    Min - Max39.0 - 108.0-28.0 - 49.040.0 - 110.0-43.0 - 46.040.0 - 102.0-34.0 - 32.0# }"},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_generic_occurrence_table.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Create Generic Occurrence Summary Table — build_generic_occurrence_table","text":"","code":"build_generic_occurrence_table(   occ_df,   filter_cond = NULL,   trt_var,   dataset,   class_var,   term_var )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_generic_occurrence_table.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Create Generic Occurrence Summary Table — build_generic_occurrence_table","text":"occ_df (data.frame) Occurrence dataset (typically ADAE, ADMH etc) filter_cond (character) Filtering condition required occ_df. trt_var (character) Arm variable used split table columns. dataset (character) Name dataset eg. \"cadae\". class_var (character) Body system organ class variable. term_var (character) Preferred term variable occ_df include table.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_generic_occurrence_table.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Create Generic Occurrence Summary Table — build_generic_occurrence_table","text":"List containing table layout object Generic Occurrence Table filtered Occurrencedata","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_generic_occurrence_table.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Create Generic Occurrence Summary Table — build_generic_occurrence_table","text":"Primary System Organ Class     Dictionary-Derived Term Placebo (N=86) Xanomeline High Dose (N=84) Xanomeline Low Dose (N=84) Patients (N=306) Total number patients least one event 65 (75.6%) 75 (89.3%) 77 (91.7%) 217 (70.9%) Total number events 281 429 412 1122 CARDIAC DISORDERS 12 (14.0%) 15 (17.9%) 13 (15.5%) 40 (13.1%) ATRIAL FIBRILLATION 1 (1.2%) 3 (3.6%) 1 (1.2%) 5 (1.6%) ATRIAL FLUTTER 0 1 (1.2%) 1 (1.2%) 2 (0.7%) ATRIAL HYPERTROPHY 1 (1.2%) 0 0 1 (0.3%) ATRIOVENTRICULAR BLOCK FIRST DEGREE 1 (1.2%) 0 1 (1.2%) 2 (0.7%) ATRIOVENTRICULAR BLOCK SECOND DEGREE 1 (1.2%) 0 0 1 (0.3%) BRADYCARDIA 1 (1.2%) 0 0 1 (0.3%) BUNDLE BRANCH BLOCK LEFT 1 (1.2%) 0 0 1 (0.3%) BUNDLE BRANCH BLOCK RIGHT 1 (1.2%) 0 1 (1.2%) 2 (0.7%) CARDIAC DISORDER 0 1 (1.2%) 0 1 (0.3%) CARDIAC FAILURE CONGESTIVE 1 (1.2%) 0 0 1 (0.3%) MYOCARDIAL INFARCTION 4 (4.7%) 4 (4.8%) 2 (2.4%) 10 (3.3%) PALPITATIONS 0 0 2 (2.4%) 2 (0.7%) SINUS ARRHYTHMIA 1 (1.2%) 0 0 1 (0.3%) SINUS BRADYCARDIA 2 (2.3%) 8 (9.5%) 7 (8.3%) 17 (5.6%) SUPRAVENTRICULAR EXTRASYSTOLES 1 (1.2%) 1 (1.2%) 1 (1.2%) 3 (1.0%) SUPRAVENTRICULAR TACHYCARDIA 0 0 1 (1.2%) 1 (0.3%) TACHYCARDIA 1 (1.2%) 0 0 1 (0.3%) VENTRICULAR EXTRASYSTOLES 0 1 (1.2%) 2 (2.4%) 3 (1.0%) VENTRICULAR HYPERTROPHY 1 (1.2%) 0 0 1 (0.3%) WOLFF-PARKINSON-WHITE SYNDROME 0 0 1 (1.2%) 1 (0.3%) CONGENITAL, FAMILIAL GENETIC DISORDERS 0 2 (2.4%) 1 (1.2%) 3 (1.0%) VENTRICULAR SEPTAL DEFECT 0 2 (2.4%) 1 (1.2%) 3 (1.0%) EAR LABYRINTH DISORDERS 1 (1.2%) 1 (1.2%) 2 (2.4%) 4 (1.3%) CERUMEN IMPACTION 0 0 1 (1.2%) 1 (0.3%) EAR PAIN 1 (1.2%) 0 0 1 (0.3%) VERTIGO 0 1 (1.2%) 1 (1.2%) 2 (0.7%) EYE DISORDERS 2 (2.3%) 1 (1.2%) 2 (2.4%) 5 (1.6%) CONJUNCTIVAL HAEMORRHAGE 0 0 1 (1.2%) 1 (0.3%) CONJUNCTIVITIS 1 (1.2%) 0 0 1 (0.3%) EYE ALLERGY 1 (1.2%) 0 0 1 (0.3%) EYE PRURITUS 1 (1.2%) 0 0 1 (0.3%) EYE SWELLING 1 (1.2%) 0 0 1 (0.3%) VISION BLURRED 0 1 (1.2%) 1 (1.2%) 2 (0.7%) GASTROINTESTINAL DISORDERS 17 (19.8%) 20 (23.8%) 14 (16.7%) 51 (16.7%) ABDOMINAL DISCOMFORT 0 1 (1.2%) 0 1 (0.3%) ABDOMINAL PAIN 1 (1.2%) 1 (1.2%) 3 (3.6%) 5 (1.6%) CONSTIPATION 1 (1.2%) 0 0 1 (0.3%) DIARRHOEA 9 (10.5%) 4 (4.8%) 4 (4.8%) 17 (5.6%) DYSPEPSIA 1 (1.2%) 0 1 (1.2%) 2 (0.7%) DYSPHAGIA 0 0 1 (1.2%) 1 (0.3%) FLATULENCE 1 (1.2%) 0 0 1 (0.3%) GASTROINTESTINAL HAEMORRHAGE 0 1 (1.2%) 0 1 (0.3%) GASTROOESOPHAGEAL REFLUX DISEASE 1 (1.2%) 0 0 1 (0.3%) GLOSSITIS 1 (1.2%) 0 0 1 (0.3%) HIATUS HERNIA 1 (1.2%) 0 0 1 (0.3%) NAUSEA 3 (3.5%) 6 (7.1%) 3 (3.6%) 12 (3.9%) RECTAL HAEMORRHAGE 0 0 1 (1.2%) 1 (0.3%) SALIVARY HYPERSECRETION 0 4 (4.8%) 0 4 (1.3%) STOMACH DISCOMFORT 0 1 (1.2%) 0 1 (0.3%) VOMITING 3 (3.5%) 7 (8.3%) 3 (3.6%) 13 (4.2%) GENERAL DISORDERS ADMINISTRATION SITE CONDITIONS 21 (24.4%) 40 (47.6%) 47 (56.0%) 108 (35.3%) APPLICATION SITE BLEEDING 0 0 1 (1.2%) 1 (0.3%) APPLICATION SITE DERMATITIS 5 (5.8%) 7 (8.3%) 9 (10.7%) 21 (6.9%) APPLICATION SITE DESQUAMATION 0 0 1 (1.2%) 1 (0.3%) APPLICATION SITE DISCHARGE 0 1 (1.2%) 0 1 (0.3%) APPLICATION SITE DISCOLOURATION 0 0 1 (1.2%) 1 (0.3%) APPLICATION SITE ERYTHEMA 3 (3.5%) 15 (17.9%) 12 (14.3%) 30 (9.8%) APPLICATION SITE INDURATION 1 (1.2%) 0 0 1 (0.3%) APPLICATION SITE IRRITATION 3 (3.5%) 9 (10.7%) 9 (10.7%) 21 (6.9%) APPLICATION SITE PAIN 0 2 (2.4%) 0 2 (0.7%) APPLICATION SITE PERSPIRATION 0 2 (2.4%) 0 2 (0.7%) APPLICATION SITE PRURITUS 6 (7.0%) 22 (26.2%) 22 (26.2%) 50 (16.3%) APPLICATION SITE REACTION 1 (1.2%) 1 (1.2%) 0 2 (0.7%) APPLICATION SITE SWELLING 0 2 (2.4%) 1 (1.2%) 3 (1.0%) APPLICATION SITE URTICARIA 0 1 (1.2%) 2 (2.4%) 3 (1.0%) APPLICATION SITE VESICLES 1 (1.2%) 6 (7.1%) 4 (4.8%) 11 (3.6%) APPLICATION SITE WARMTH 0 0 1 (1.2%) 1 (0.3%) ASTHENIA 1 (1.2%) 1 (1.2%) 0 2 (0.7%) CHEST DISCOMFORT 0 2 (2.4%) 0 2 (0.7%) CHEST PAIN 0 2 (2.4%) 0 2 (0.7%) CHILLS 1 (1.2%) 1 (1.2%) 1 (1.2%) 3 (1.0%) FATIGUE 1 (1.2%) 5 (6.0%) 5 (6.0%) 11 (3.6%) FEELING ABNORMAL 0 1 (1.2%) 0 1 (0.3%) FEELING COLD 0 1 (1.2%) 0 1 (0.3%) INFLAMMATION 0 0 1 (1.2%) 1 (0.3%) MALAISE 0 2 (2.4%) 1 (1.2%) 3 (1.0%) OEDEMA 0 0 2 (2.4%) 2 (0.7%) OEDEMA PERIPHERAL 2 (2.3%) 2 (2.4%) 1 (1.2%) 5 (1.6%) PAIN 0 1 (1.2%) 1 (1.2%) 2 (0.7%) PYREXIA 2 (2.3%) 1 (1.2%) 0 3 (1.0%) SECRETION DISCHARGE 0 0 1 (1.2%) 1 (0.3%) SUDDEN DEATH 0 0 1 (1.2%) 1 (0.3%) SWELLING 0 0 1 (1.2%) 1 (0.3%) ULCER 0 0 1 (1.2%) 1 (0.3%) HEPATOBILIARY DISORDERS 1 (1.2%) 0 0 1 (0.3%) HYPERBILIRUBINAEMIA 1 (1.2%) 0 0 1 (0.3%) IMMUNE SYSTEM DISORDERS 0 0 1 (1.2%) 1 (0.3%) HYPERSENSITIVITY 0 0 1 (1.2%) 1 (0.3%) INFECTIONS INFESTATIONS 16 (18.6%) 13 (15.5%) 9 (10.7%) 38 (12.4%) BRONCHITIS 1 (1.2%) 0 0 1 (0.3%) CELLULITIS 0 0 1 (1.2%) 1 (0.3%) CERVICITIS 1 (1.2%) 0 0 1 (0.3%) CYSTITIS 1 (1.2%) 1 (1.2%) 0 2 (0.7%) EAR INFECTION 2 (2.3%) 0 0 2 (0.7%) GASTROENTERITIS VIRAL 1 (1.2%) 0 0 1 (0.3%) HORDEOLUM 0 1 (1.2%) 0 1 (0.3%) INFLUENZA 1 (1.2%) 1 (1.2%) 1 (1.2%) 3 (1.0%) LOCALISED INFECTION 1 (1.2%) 0 0 1 (0.3%) LOWER RESPIRATORY TRACT INFECTION 0 1 (1.2%) 0 1 (0.3%) NASOPHARYNGITIS 2 (2.3%) 6 (7.1%) 4 (4.8%) 12 (3.9%) PNEUMONIA 0 0 1 (1.2%) 1 (0.3%) RHINITIS 0 1 (1.2%) 0 1 (0.3%) UPPER RESPIRATORY TRACT INFECTION 6 (7.0%) 3 (3.6%) 1 (1.2%) 10 (3.3%) URINARY TRACT INFECTION 2 (2.3%) 1 (1.2%) 0 3 (1.0%) VAGINAL MYCOSIS 1 (1.2%) 0 0 1 (0.3%) VIRAL INFECTION 0 0 1 (1.2%) 1 (0.3%) INJURY, POISONING PROCEDURAL COMPLICATIONS 4 (4.7%) 5 (6.0%) 5 (6.0%) 14 (4.6%) CONTUSION 1 (1.2%) 2 (2.4%) 1 (1.2%) 4 (1.3%) EXCORIATION 2 (2.3%) 1 (1.2%) 1 (1.2%) 4 (1.3%) FACIAL BONES FRACTURE 0 1 (1.2%) 0 1 (0.3%) FALL 1 (1.2%) 1 (1.2%) 2 (2.4%) 4 (1.3%) HIP FRACTURE 1 (1.2%) 2 (2.4%) 0 3 (1.0%) JOINT DISLOCATION 0 0 1 (1.2%) 1 (0.3%) SKIN LACERATION 1 (1.2%) 0 2 (2.4%) 3 (1.0%) WOUND 0 0 1 (1.2%) 1 (0.3%) INVESTIGATIONS 10 (11.6%) 6 (7.1%) 6 (7.1%) 22 (7.2%) BIOPSY 0 1 (1.2%) 0 1 (0.3%) BIOPSY PROSTATE 0 1 (1.2%) 0 1 (0.3%) BLOOD ALKALINE PHOSPHATASE INCREASED 1 (1.2%) 0 0 1 (0.3%) BLOOD CHOLESTEROL INCREASED 0 1 (1.2%) 0 1 (0.3%) BLOOD CREATINE PHOSPHOKINASE INCREASED 1 (1.2%) 0 0 1 (0.3%) BLOOD GLUCOSE INCREASED 0 1 (1.2%) 1 (1.2%) 2 (0.7%) BLOOD URINE PRESENT 1 (1.2%) 0 0 1 (0.3%) BODY TEMPERATURE INCREASED 0 0 1 (1.2%) 1 (0.3%) CYSTOSCOPY 1 (1.2%) 0 0 1 (0.3%) ELECTROCARDIOGRAM ST SEGMENT DEPRESSION 4 (4.7%) 0 1 (1.2%) 5 (1.6%) ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED 1 (1.2%) 0 1 (1.2%) 2 (0.7%) ELECTROCARDIOGRAM T WAVE INVERSION 2 (2.3%) 1 (1.2%) 1 (1.2%) 4 (1.3%) HEART RATE INCREASED 1 (1.2%) 0 0 1 (0.3%) HEART RATE IRREGULAR 1 (1.2%) 0 0 1 (0.3%) NASAL MUCOSA BIOPSY 0 0 1 (1.2%) 1 (0.3%) WEIGHT DECREASED 0 1 (1.2%) 0 1 (0.3%) METABOLISM NUTRITION DISORDERS 6 (7.0%) 2 (2.4%) 1 (1.2%) 9 (2.9%) DECREASED APPETITE 1 (1.2%) 1 (1.2%) 0 2 (0.7%) DEHYDRATION 1 (1.2%) 0 0 1 (0.3%) DIABETES MELLITUS 1 (1.2%) 0 0 1 (0.3%) FOOD CRAVING 1 (1.2%) 0 1 (1.2%) 2 (0.7%) HYPONATRAEMIA 1 (1.2%) 0 0 1 (0.3%) INCREASED APPETITE 1 (1.2%) 1 (1.2%) 0 2 (0.7%) MUSCULOSKELETAL CONNECTIVE TISSUE DISORDERS 4 (4.7%) 7 (8.3%) 7 (8.3%) 18 (5.9%) ARTHRALGIA 1 (1.2%) 1 (1.2%) 2 (2.4%) 4 (1.3%) ARTHRITIS 0 1 (1.2%) 0 1 (0.3%) BACK PAIN 1 (1.2%) 3 (3.6%) 1 (1.2%) 5 (1.6%) FLANK PAIN 0 1 (1.2%) 0 1 (0.3%) MUSCLE SPASMS 0 1 (1.2%) 1 (1.2%) 2 (0.7%) MUSCULAR WEAKNESS 0 0 1 (1.2%) 1 (0.3%) MYALGIA 0 1 (1.2%) 0 1 (0.3%) PAIN EXTREMITY 1 (1.2%) 0 0 1 (0.3%) SHOULDER PAIN 1 (1.2%) 0 2 (2.4%) 3 (1.0%) NEOPLASMS BENIGN, MALIGNANT UNSPECIFIED (INCL CYSTS POLYPS) 0 1 (1.2%) 2 (2.4%) 3 (1.0%) COLON CANCER 0 0 1 (1.2%) 1 (0.3%) MALIGNANT FIBROUS HISTIOCYTOMA 0 0 1 (1.2%) 1 (0.3%) PROSTATE CANCER 0 1 (1.2%) 0 1 (0.3%) NERVOUS SYSTEM DISORDERS 8 (9.3%) 25 (29.8%) 20 (23.8%) 53 (17.3%) AMNESIA 0 1 (1.2%) 0 1 (0.3%) BALANCE DISORDER 0 0 1 (1.2%) 1 (0.3%) BURNING SENSATION 0 2 (2.4%) 0 2 (0.7%) COGNITIVE DISORDER 0 1 (1.2%) 0 1 (0.3%) COMPLEX PARTIAL SEIZURES 0 0 1 (1.2%) 1 (0.3%) COORDINATION ABNORMAL 0 0 1 (1.2%) 1 (0.3%) DIZZINESS 2 (2.3%) 11 (13.1%) 8 (9.5%) 21 (6.9%) HEADACHE 3 (3.5%) 5 (6.0%) 3 (3.6%) 11 (3.6%) HEMIANOPIA HOMONYMOUS 0 0 1 (1.2%) 1 (0.3%) HYPERSOMNIA 0 1 (1.2%) 0 1 (0.3%) LETHARGY 0 1 (1.2%) 1 (1.2%) 2 (0.7%) PARAESTHESIA 0 1 (1.2%) 0 1 (0.3%) PARAESTHESIA ORAL 0 0 1 (1.2%) 1 (0.3%) PARKINSON'S DISEASE 1 (1.2%) 0 0 1 (0.3%) PAROSMIA 0 1 (1.2%) 0 1 (0.3%) PARTIAL SEIZURES SECONDARY GENERALISATION 0 1 (1.2%) 0 1 (0.3%) PSYCHOMOTOR HYPERACTIVITY 1 (1.2%) 0 0 1 (0.3%) SOMNOLENCE 2 (2.3%) 1 (1.2%) 3 (3.6%) 6 (2.0%) STUPOR 0 0 1 (1.2%) 1 (0.3%) SYNCOPE 0 3 (3.6%) 4 (4.8%) 7 (2.3%) SYNCOPE VASOVAGAL 0 1 (1.2%) 0 1 (0.3%) TRANSIENT ISCHAEMIC ATTACK 0 1 (1.2%) 2 (2.4%) 3 (1.0%) PSYCHIATRIC DISORDERS 10 (11.6%) 8 (9.5%) 10 (11.9%) 28 (9.2%) AGITATION 2 (2.3%) 1 (1.2%) 2 (2.4%) 5 (1.6%) ANXIETY 0 0 3 (3.6%) 3 (1.0%) COMPLETED SUICIDE 1 (1.2%) 0 0 1 (0.3%) CONFUSIONAL STATE 2 (2.3%) 1 (1.2%) 3 (3.6%) 6 (2.0%) DELIRIUM 0 1 (1.2%) 0 1 (0.3%) DELUSION 1 (1.2%) 1 (1.2%) 0 2 (0.7%) DEPRESSED MOOD 0 0 1 (1.2%) 1 (0.3%) DISORIENTATION 1 (1.2%) 0 0 1 (0.3%) HALLUCINATION 0 1 (1.2%) 0 1 (0.3%) HALLUCINATION, VISUAL 0 1 (1.2%) 0 1 (0.3%) INSOMNIA 2 (2.3%) 2 (2.4%) 0 4 (1.3%) IRRITABILITY 1 (1.2%) 0 1 (1.2%) 2 (0.7%) LIBIDO DECREASED 0 1 (1.2%) 0 1 (0.3%) LISTLESS 0 1 (1.2%) 0 1 (0.3%) NIGHTMARE 0 1 (1.2%) 0 1 (0.3%) RESTLESSNESS 0 0 1 (1.2%) 1 (0.3%) RENAL URINARY DISORDERS 4 (4.7%) 3 (3.6%) 3 (3.6%) 10 (3.3%) CALCULUS URETHRAL 0 1 (1.2%) 0 1 (0.3%) DYSURIA 1 (1.2%) 0 1 (1.2%) 2 (0.7%) INCONTINENCE 0 0 1 (1.2%) 1 (0.3%) MICTURITION URGENCY 1 (1.2%) 1 (1.2%) 1 (1.2%) 3 (1.0%) NEPHROLITHIASIS 1 (1.2%) 1 (1.2%) 0 2 (0.7%) POLLAKIURIA 1 (1.2%) 0 0 1 (0.3%) REPRODUCTIVE SYSTEM BREAST DISORDERS 2 (2.3%) 1 (1.2%) 0 3 (1.0%) BENIGN PROSTATIC HYPERPLASIA 1 (1.2%) 1 (1.2%) 0 2 (0.7%) PELVIC PAIN 1 (1.2%) 0 0 1 (0.3%) RESPIRATORY, THORACIC MEDIASTINAL DISORDERS 8 (9.3%) 10 (11.9%) 9 (10.7%) 27 (8.8%) ALLERGIC GRANULOMATOUS ANGIITIS 0 1 (1.2%) 0 1 (0.3%) COUGH 1 (1.2%) 5 (6.0%) 5 (6.0%) 11 (3.6%) DYSPHONIA 0 0 1 (1.2%) 1 (0.3%) DYSPNOEA 1 (1.2%) 1 (1.2%) 1 (1.2%) 3 (1.0%) EMPHYSEMA 1 (1.2%) 0 0 1 (0.3%) EPISTAXIS 0 2 (2.4%) 1 (1.2%) 3 (1.0%) HAEMOPTYSIS 1 (1.2%) 0 0 1 (0.3%) NASAL CONGESTION 3 (3.5%) 3 (3.6%) 1 (1.2%) 7 (2.3%) PHARYNGEAL ERYTHEMA 0 1 (1.2%) 0 1 (0.3%) PHARYNGOLARYNGEAL PAIN 0 1 (1.2%) 1 (1.2%) 2 (0.7%) POSTNASAL DRIP 1 (1.2%) 0 0 1 (0.3%) PRODUCTIVE COUGH 0 1 (1.2%) 0 1 (0.3%) RALES 1 (1.2%) 0 0 1 (0.3%) RESPIRATORY TRACT CONGESTION 0 1 (1.2%) 0 1 (0.3%) RHINORRHOEA 0 1 (1.2%) 1 (1.2%) 2 (0.7%) SKIN SUBCUTANEOUS TISSUE DISORDERS 20 (23.3%) 39 (46.4%) 39 (46.4%) 98 (32.0%) ACTINIC KERATOSIS 0 1 (1.2%) 0 1 (0.3%) ALOPECIA 1 (1.2%) 0 0 1 (0.3%) BLISTER 0 1 (1.2%) 5 (6.0%) 6 (2.0%) COLD SWEAT 1 (1.2%) 0 0 1 (0.3%) DERMATITIS CONTACT 0 0 1 (1.2%) 1 (0.3%) DRUG ERUPTION 1 (1.2%) 0 0 1 (0.3%) ERYTHEMA 8 (9.3%) 14 (16.7%) 14 (16.7%) 36 (11.8%) HYPERHIDROSIS 2 (2.3%) 8 (9.5%) 4 (4.8%) 14 (4.6%) PRURITUS 8 (9.3%) 25 (29.8%) 21 (25.0%) 54 (17.6%) PRURITUS GENERALISED 0 1 (1.2%) 1 (1.2%) 2 (0.7%) RASH 5 (5.8%) 8 (9.5%) 13 (15.5%) 26 (8.5%) RASH ERYTHEMATOUS 0 0 1 (1.2%) 1 (0.3%) RASH MACULO-PAPULAR 0 1 (1.2%) 0 1 (0.3%) RASH PRURITIC 0 2 (2.4%) 1 (1.2%) 3 (1.0%) SKIN EXFOLIATION 0 0 1 (1.2%) 1 (0.3%) SKIN IRRITATION 3 (3.5%) 5 (6.0%) 6 (7.1%) 14 (4.6%) SKIN ODOUR ABNORMAL 0 1 (1.2%) 0 1 (0.3%) SKIN ULCER 1 (1.2%) 0 0 1 (0.3%) URTICARIA 0 1 (1.2%) 1 (1.2%) 2 (0.7%) SOCIAL CIRCUMSTANCES 0 1 (1.2%) 0 1 (0.3%) ALCOHOL USE 0 1 (1.2%) 0 1 (0.3%) SURGICAL MEDICAL PROCEDURES 2 (2.3%) 2 (2.4%) 1 (1.2%) 5 (1.6%) ACROCHORDON EXCISION 0 1 (1.2%) 0 1 (0.3%) CATARACT OPERATION 1 (1.2%) 0 1 (1.2%) 2 (0.7%) EYE LASER SURGERY 1 (1.2%) 0 0 1 (0.3%) SKIN LESION EXCISION 0 1 (1.2%) 0 1 (0.3%) VASCULAR DISORDERS 3 (3.5%) 1 (1.2%) 3 (3.6%) 7 (2.3%) HOT FLUSH 0 0 1 (1.2%) 1 (0.3%) HYPERTENSION 1 (1.2%) 0 1 (1.2%) 2 (0.7%) HYPOTENSION 2 (2.3%) 0 1 (1.2%) 3 (1.0%) ORTHOSTATIC HYPOTENSION 1 (1.2%) 0 0 1 (0.3%) WOUND HAEMORRHAGE 0 1 (1.2%) 0 1 (0.3%)","code":"library(rtables) library(tern) library(dplyr)  adsl <- pharmaverseadam::adsl |> drop_missing_cols() adae <- pharmaverseadam::adae |> drop_missing_cols() adae <- filter(adae, SAFFL == \"Y\")  lyt <- build_generic_occurrence_table(   occ_df = adae,   filter_cond = NULL,   trt_var = \"ARM\",   dataset = \"adae\",   class_var = \"AESOC\",   term_var = \"AEDECOD\" ) tbl <- build_table(lyt = lyt$lyt, df = lyt$df_out, alt_counts_df = adsl)  # \\dontrun{ tt_to_flextable(tbl) .cl-8fb75f62{table-layout:auto;}.cl-8fa0d346{font-family:'Arial';font-size:9pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-8fa0d347{font-family:'Arial';font-size:9pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-8fa8bce6{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-8fa8bce7{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:3pt;padding-top:0;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-8fa8bce8{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:0.3pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-8fa8bce9{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-8fa8bcea{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:23pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-8fa8bceb{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:1pt;padding-top:1pt;padding-left:34.3pt;padding-right:0.3pt;line-height: 1;background-color:transparent;}.cl-8fa90b06{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa90b07{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa90b08{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa90b09{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa90b0a{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa90b0b{background-color:transparent;vertical-align: middle;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa90b0c{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa90b0d{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa90b0e{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa90b0f{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa90b10{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa93220{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa93221{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa93222{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa93223{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa93224{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa93225{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa93226{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa93227{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa93228{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa93229{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa9322a{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa94440{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa94441{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa94442{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa94443{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0.5pt solid rgba(102, 102, 102, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa94444{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa94445{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa94446{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-8fa94447{background-color:transparent;vertical-align: top;border-bottom: 0.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0.5pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}Primary System Organ Class  Dictionary-Derived TermPlacebo (N=86)Xanomeline High Dose (N=84)Xanomeline Low Dose (N=84)All Patients (N=306)Total number of patients with at least one event65 (75.6%)75 (89.3%)77 (91.7%)217 (70.9%)Total number of events2814294121122    CARDIAC DISORDERS12 (14.0%)15 (17.9%)13 (15.5%)40 (13.1%)      ATRIAL FIBRILLATION1 (1.2%)3 (3.6%)1 (1.2%)5 (1.6%)      ATRIAL FLUTTER01 (1.2%)1 (1.2%)2 (0.7%)      ATRIAL HYPERTROPHY1 (1.2%)001 (0.3%)      ATRIOVENTRICULAR BLOCK FIRST DEGREE1 (1.2%)01 (1.2%)2 (0.7%)      ATRIOVENTRICULAR BLOCK SECOND DEGREE1 (1.2%)001 (0.3%)      BRADYCARDIA1 (1.2%)001 (0.3%)      BUNDLE BRANCH BLOCK LEFT1 (1.2%)001 (0.3%)      BUNDLE BRANCH BLOCK RIGHT1 (1.2%)01 (1.2%)2 (0.7%)      CARDIAC DISORDER01 (1.2%)01 (0.3%)      CARDIAC FAILURE CONGESTIVE1 (1.2%)001 (0.3%)      MYOCARDIAL INFARCTION4 (4.7%)4 (4.8%)2 (2.4%)10 (3.3%)      PALPITATIONS002 (2.4%)2 (0.7%)      SINUS ARRHYTHMIA1 (1.2%)001 (0.3%)      SINUS BRADYCARDIA2 (2.3%)8 (9.5%)7 (8.3%)17 (5.6%)      SUPRAVENTRICULAR EXTRASYSTOLES1 (1.2%)1 (1.2%)1 (1.2%)3 (1.0%)      SUPRAVENTRICULAR TACHYCARDIA001 (1.2%)1 (0.3%)      TACHYCARDIA1 (1.2%)001 (0.3%)      VENTRICULAR EXTRASYSTOLES01 (1.2%)2 (2.4%)3 (1.0%)      VENTRICULAR HYPERTROPHY1 (1.2%)001 (0.3%)      WOLFF-PARKINSON-WHITE SYNDROME001 (1.2%)1 (0.3%)    CONGENITAL, FAMILIAL AND GENETIC DISORDERS02 (2.4%)1 (1.2%)3 (1.0%)      VENTRICULAR SEPTAL DEFECT02 (2.4%)1 (1.2%)3 (1.0%)    EAR AND LABYRINTH DISORDERS1 (1.2%)1 (1.2%)2 (2.4%)4 (1.3%)      CERUMEN IMPACTION001 (1.2%)1 (0.3%)      EAR PAIN1 (1.2%)001 (0.3%)      VERTIGO01 (1.2%)1 (1.2%)2 (0.7%)    EYE DISORDERS2 (2.3%)1 (1.2%)2 (2.4%)5 (1.6%)      CONJUNCTIVAL HAEMORRHAGE001 (1.2%)1 (0.3%)      CONJUNCTIVITIS1 (1.2%)001 (0.3%)      EYE ALLERGY1 (1.2%)001 (0.3%)      EYE PRURITUS1 (1.2%)001 (0.3%)      EYE SWELLING1 (1.2%)001 (0.3%)      VISION BLURRED01 (1.2%)1 (1.2%)2 (0.7%)    GASTROINTESTINAL DISORDERS17 (19.8%)20 (23.8%)14 (16.7%)51 (16.7%)      ABDOMINAL DISCOMFORT01 (1.2%)01 (0.3%)      ABDOMINAL PAIN1 (1.2%)1 (1.2%)3 (3.6%)5 (1.6%)      CONSTIPATION1 (1.2%)001 (0.3%)      DIARRHOEA9 (10.5%)4 (4.8%)4 (4.8%)17 (5.6%)      DYSPEPSIA1 (1.2%)01 (1.2%)2 (0.7%)      DYSPHAGIA001 (1.2%)1 (0.3%)      FLATULENCE1 (1.2%)001 (0.3%)      GASTROINTESTINAL HAEMORRHAGE01 (1.2%)01 (0.3%)      GASTROOESOPHAGEAL REFLUX DISEASE1 (1.2%)001 (0.3%)      GLOSSITIS1 (1.2%)001 (0.3%)      HIATUS HERNIA1 (1.2%)001 (0.3%)      NAUSEA3 (3.5%)6 (7.1%)3 (3.6%)12 (3.9%)      RECTAL HAEMORRHAGE001 (1.2%)1 (0.3%)      SALIVARY HYPERSECRETION04 (4.8%)04 (1.3%)      STOMACH DISCOMFORT01 (1.2%)01 (0.3%)      VOMITING3 (3.5%)7 (8.3%)3 (3.6%)13 (4.2%)    GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS21 (24.4%)40 (47.6%)47 (56.0%)108 (35.3%)      APPLICATION SITE BLEEDING001 (1.2%)1 (0.3%)      APPLICATION SITE DERMATITIS5 (5.8%)7 (8.3%)9 (10.7%)21 (6.9%)      APPLICATION SITE DESQUAMATION001 (1.2%)1 (0.3%)      APPLICATION SITE DISCHARGE01 (1.2%)01 (0.3%)      APPLICATION SITE DISCOLOURATION001 (1.2%)1 (0.3%)      APPLICATION SITE ERYTHEMA3 (3.5%)15 (17.9%)12 (14.3%)30 (9.8%)      APPLICATION SITE INDURATION1 (1.2%)001 (0.3%)      APPLICATION SITE IRRITATION3 (3.5%)9 (10.7%)9 (10.7%)21 (6.9%)      APPLICATION SITE PAIN02 (2.4%)02 (0.7%)      APPLICATION SITE PERSPIRATION02 (2.4%)02 (0.7%)      APPLICATION SITE PRURITUS6 (7.0%)22 (26.2%)22 (26.2%)50 (16.3%)      APPLICATION SITE REACTION1 (1.2%)1 (1.2%)02 (0.7%)      APPLICATION SITE SWELLING02 (2.4%)1 (1.2%)3 (1.0%)      APPLICATION SITE URTICARIA01 (1.2%)2 (2.4%)3 (1.0%)      APPLICATION SITE VESICLES1 (1.2%)6 (7.1%)4 (4.8%)11 (3.6%)      APPLICATION SITE WARMTH001 (1.2%)1 (0.3%)      ASTHENIA1 (1.2%)1 (1.2%)02 (0.7%)      CHEST DISCOMFORT02 (2.4%)02 (0.7%)      CHEST PAIN02 (2.4%)02 (0.7%)      CHILLS1 (1.2%)1 (1.2%)1 (1.2%)3 (1.0%)      FATIGUE1 (1.2%)5 (6.0%)5 (6.0%)11 (3.6%)      FEELING ABNORMAL01 (1.2%)01 (0.3%)      FEELING COLD01 (1.2%)01 (0.3%)      INFLAMMATION001 (1.2%)1 (0.3%)      MALAISE02 (2.4%)1 (1.2%)3 (1.0%)      OEDEMA002 (2.4%)2 (0.7%)      OEDEMA PERIPHERAL2 (2.3%)2 (2.4%)1 (1.2%)5 (1.6%)      PAIN01 (1.2%)1 (1.2%)2 (0.7%)      PYREXIA2 (2.3%)1 (1.2%)03 (1.0%)      SECRETION DISCHARGE001 (1.2%)1 (0.3%)      SUDDEN DEATH001 (1.2%)1 (0.3%)      SWELLING001 (1.2%)1 (0.3%)      ULCER001 (1.2%)1 (0.3%)    HEPATOBILIARY DISORDERS1 (1.2%)001 (0.3%)      HYPERBILIRUBINAEMIA1 (1.2%)001 (0.3%)    IMMUNE SYSTEM DISORDERS001 (1.2%)1 (0.3%)      HYPERSENSITIVITY001 (1.2%)1 (0.3%)    INFECTIONS AND INFESTATIONS16 (18.6%)13 (15.5%)9 (10.7%)38 (12.4%)      BRONCHITIS1 (1.2%)001 (0.3%)      CELLULITIS001 (1.2%)1 (0.3%)      CERVICITIS1 (1.2%)001 (0.3%)      CYSTITIS1 (1.2%)1 (1.2%)02 (0.7%)      EAR INFECTION2 (2.3%)002 (0.7%)      GASTROENTERITIS VIRAL1 (1.2%)001 (0.3%)      HORDEOLUM01 (1.2%)01 (0.3%)      INFLUENZA1 (1.2%)1 (1.2%)1 (1.2%)3 (1.0%)      LOCALISED INFECTION1 (1.2%)001 (0.3%)      LOWER RESPIRATORY TRACT INFECTION01 (1.2%)01 (0.3%)      NASOPHARYNGITIS2 (2.3%)6 (7.1%)4 (4.8%)12 (3.9%)      PNEUMONIA001 (1.2%)1 (0.3%)      RHINITIS01 (1.2%)01 (0.3%)      UPPER RESPIRATORY TRACT INFECTION6 (7.0%)3 (3.6%)1 (1.2%)10 (3.3%)      URINARY TRACT INFECTION2 (2.3%)1 (1.2%)03 (1.0%)      VAGINAL MYCOSIS1 (1.2%)001 (0.3%)      VIRAL INFECTION001 (1.2%)1 (0.3%)    INJURY, POISONING AND PROCEDURAL COMPLICATIONS4 (4.7%)5 (6.0%)5 (6.0%)14 (4.6%)      CONTUSION1 (1.2%)2 (2.4%)1 (1.2%)4 (1.3%)      EXCORIATION2 (2.3%)1 (1.2%)1 (1.2%)4 (1.3%)      FACIAL BONES FRACTURE01 (1.2%)01 (0.3%)      FALL1 (1.2%)1 (1.2%)2 (2.4%)4 (1.3%)      HIP FRACTURE1 (1.2%)2 (2.4%)03 (1.0%)      JOINT DISLOCATION001 (1.2%)1 (0.3%)      SKIN LACERATION1 (1.2%)02 (2.4%)3 (1.0%)      WOUND001 (1.2%)1 (0.3%)    INVESTIGATIONS10 (11.6%)6 (7.1%)6 (7.1%)22 (7.2%)      BIOPSY01 (1.2%)01 (0.3%)      BIOPSY PROSTATE01 (1.2%)01 (0.3%)      BLOOD ALKALINE PHOSPHATASE INCREASED1 (1.2%)001 (0.3%)      BLOOD CHOLESTEROL INCREASED01 (1.2%)01 (0.3%)      BLOOD CREATINE PHOSPHOKINASE INCREASED1 (1.2%)001 (0.3%)      BLOOD GLUCOSE INCREASED01 (1.2%)1 (1.2%)2 (0.7%)      BLOOD URINE PRESENT1 (1.2%)001 (0.3%)      BODY TEMPERATURE INCREASED001 (1.2%)1 (0.3%)      CYSTOSCOPY1 (1.2%)001 (0.3%)      ELECTROCARDIOGRAM ST SEGMENT DEPRESSION4 (4.7%)01 (1.2%)5 (1.6%)      ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED1 (1.2%)01 (1.2%)2 (0.7%)      ELECTROCARDIOGRAM T WAVE INVERSION2 (2.3%)1 (1.2%)1 (1.2%)4 (1.3%)      HEART RATE INCREASED1 (1.2%)001 (0.3%)      HEART RATE IRREGULAR1 (1.2%)001 (0.3%)      NASAL MUCOSA BIOPSY001 (1.2%)1 (0.3%)      WEIGHT DECREASED01 (1.2%)01 (0.3%)    METABOLISM AND NUTRITION DISORDERS6 (7.0%)2 (2.4%)1 (1.2%)9 (2.9%)      DECREASED APPETITE1 (1.2%)1 (1.2%)02 (0.7%)      DEHYDRATION1 (1.2%)001 (0.3%)      DIABETES MELLITUS1 (1.2%)001 (0.3%)      FOOD CRAVING1 (1.2%)01 (1.2%)2 (0.7%)      HYPONATRAEMIA1 (1.2%)001 (0.3%)      INCREASED APPETITE1 (1.2%)1 (1.2%)02 (0.7%)    MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS4 (4.7%)7 (8.3%)7 (8.3%)18 (5.9%)      ARTHRALGIA1 (1.2%)1 (1.2%)2 (2.4%)4 (1.3%)      ARTHRITIS01 (1.2%)01 (0.3%)      BACK PAIN1 (1.2%)3 (3.6%)1 (1.2%)5 (1.6%)      FLANK PAIN01 (1.2%)01 (0.3%)      MUSCLE SPASMS01 (1.2%)1 (1.2%)2 (0.7%)      MUSCULAR WEAKNESS001 (1.2%)1 (0.3%)      MYALGIA01 (1.2%)01 (0.3%)      PAIN IN EXTREMITY1 (1.2%)001 (0.3%)      SHOULDER PAIN1 (1.2%)02 (2.4%)3 (1.0%)    NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)01 (1.2%)2 (2.4%)3 (1.0%)      COLON CANCER001 (1.2%)1 (0.3%)      MALIGNANT FIBROUS HISTIOCYTOMA001 (1.2%)1 (0.3%)      PROSTATE CANCER01 (1.2%)01 (0.3%)    NERVOUS SYSTEM DISORDERS8 (9.3%)25 (29.8%)20 (23.8%)53 (17.3%)      AMNESIA01 (1.2%)01 (0.3%)      BALANCE DISORDER001 (1.2%)1 (0.3%)      BURNING SENSATION02 (2.4%)02 (0.7%)      COGNITIVE DISORDER01 (1.2%)01 (0.3%)      COMPLEX PARTIAL SEIZURES001 (1.2%)1 (0.3%)      COORDINATION ABNORMAL001 (1.2%)1 (0.3%)      DIZZINESS2 (2.3%)11 (13.1%)8 (9.5%)21 (6.9%)      HEADACHE3 (3.5%)5 (6.0%)3 (3.6%)11 (3.6%)      HEMIANOPIA HOMONYMOUS001 (1.2%)1 (0.3%)      HYPERSOMNIA01 (1.2%)01 (0.3%)      LETHARGY01 (1.2%)1 (1.2%)2 (0.7%)      PARAESTHESIA01 (1.2%)01 (0.3%)      PARAESTHESIA ORAL001 (1.2%)1 (0.3%)      PARKINSON'S DISEASE1 (1.2%)001 (0.3%)      PAROSMIA01 (1.2%)01 (0.3%)      PARTIAL SEIZURES WITH SECONDARY GENERALISATION01 (1.2%)01 (0.3%)      PSYCHOMOTOR HYPERACTIVITY1 (1.2%)001 (0.3%)      SOMNOLENCE2 (2.3%)1 (1.2%)3 (3.6%)6 (2.0%)      STUPOR001 (1.2%)1 (0.3%)      SYNCOPE03 (3.6%)4 (4.8%)7 (2.3%)      SYNCOPE VASOVAGAL01 (1.2%)01 (0.3%)      TRANSIENT ISCHAEMIC ATTACK01 (1.2%)2 (2.4%)3 (1.0%)    PSYCHIATRIC DISORDERS10 (11.6%)8 (9.5%)10 (11.9%)28 (9.2%)      AGITATION2 (2.3%)1 (1.2%)2 (2.4%)5 (1.6%)      ANXIETY003 (3.6%)3 (1.0%)      COMPLETED SUICIDE1 (1.2%)001 (0.3%)      CONFUSIONAL STATE2 (2.3%)1 (1.2%)3 (3.6%)6 (2.0%)      DELIRIUM01 (1.2%)01 (0.3%)      DELUSION1 (1.2%)1 (1.2%)02 (0.7%)      DEPRESSED MOOD001 (1.2%)1 (0.3%)      DISORIENTATION1 (1.2%)001 (0.3%)      HALLUCINATION01 (1.2%)01 (0.3%)      HALLUCINATION, VISUAL01 (1.2%)01 (0.3%)      INSOMNIA2 (2.3%)2 (2.4%)04 (1.3%)      IRRITABILITY1 (1.2%)01 (1.2%)2 (0.7%)      LIBIDO DECREASED01 (1.2%)01 (0.3%)      LISTLESS01 (1.2%)01 (0.3%)      NIGHTMARE01 (1.2%)01 (0.3%)      RESTLESSNESS001 (1.2%)1 (0.3%)    RENAL AND URINARY DISORDERS4 (4.7%)3 (3.6%)3 (3.6%)10 (3.3%)      CALCULUS URETHRAL01 (1.2%)01 (0.3%)      DYSURIA1 (1.2%)01 (1.2%)2 (0.7%)      INCONTINENCE001 (1.2%)1 (0.3%)      MICTURITION URGENCY1 (1.2%)1 (1.2%)1 (1.2%)3 (1.0%)      NEPHROLITHIASIS1 (1.2%)1 (1.2%)02 (0.7%)      POLLAKIURIA1 (1.2%)001 (0.3%)    REPRODUCTIVE SYSTEM AND BREAST DISORDERS2 (2.3%)1 (1.2%)03 (1.0%)      BENIGN PROSTATIC HYPERPLASIA1 (1.2%)1 (1.2%)02 (0.7%)      PELVIC PAIN1 (1.2%)001 (0.3%)    RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS8 (9.3%)10 (11.9%)9 (10.7%)27 (8.8%)      ALLERGIC GRANULOMATOUS ANGIITIS01 (1.2%)01 (0.3%)      COUGH1 (1.2%)5 (6.0%)5 (6.0%)11 (3.6%)      DYSPHONIA001 (1.2%)1 (0.3%)      DYSPNOEA1 (1.2%)1 (1.2%)1 (1.2%)3 (1.0%)      EMPHYSEMA1 (1.2%)001 (0.3%)      EPISTAXIS02 (2.4%)1 (1.2%)3 (1.0%)      HAEMOPTYSIS1 (1.2%)001 (0.3%)      NASAL CONGESTION3 (3.5%)3 (3.6%)1 (1.2%)7 (2.3%)      PHARYNGEAL ERYTHEMA01 (1.2%)01 (0.3%)      PHARYNGOLARYNGEAL PAIN01 (1.2%)1 (1.2%)2 (0.7%)      POSTNASAL DRIP1 (1.2%)001 (0.3%)      PRODUCTIVE COUGH01 (1.2%)01 (0.3%)      RALES1 (1.2%)001 (0.3%)      RESPIRATORY TRACT CONGESTION01 (1.2%)01 (0.3%)      RHINORRHOEA01 (1.2%)1 (1.2%)2 (0.7%)    SKIN AND SUBCUTANEOUS TISSUE DISORDERS20 (23.3%)39 (46.4%)39 (46.4%)98 (32.0%)      ACTINIC KERATOSIS01 (1.2%)01 (0.3%)      ALOPECIA1 (1.2%)001 (0.3%)      BLISTER01 (1.2%)5 (6.0%)6 (2.0%)      COLD SWEAT1 (1.2%)001 (0.3%)      DERMATITIS CONTACT001 (1.2%)1 (0.3%)      DRUG ERUPTION1 (1.2%)001 (0.3%)      ERYTHEMA8 (9.3%)14 (16.7%)14 (16.7%)36 (11.8%)      HYPERHIDROSIS2 (2.3%)8 (9.5%)4 (4.8%)14 (4.6%)      PRURITUS8 (9.3%)25 (29.8%)21 (25.0%)54 (17.6%)      PRURITUS GENERALISED01 (1.2%)1 (1.2%)2 (0.7%)      RASH5 (5.8%)8 (9.5%)13 (15.5%)26 (8.5%)      RASH ERYTHEMATOUS001 (1.2%)1 (0.3%)      RASH MACULO-PAPULAR01 (1.2%)01 (0.3%)      RASH PRURITIC02 (2.4%)1 (1.2%)3 (1.0%)      SKIN EXFOLIATION001 (1.2%)1 (0.3%)      SKIN IRRITATION3 (3.5%)5 (6.0%)6 (7.1%)14 (4.6%)      SKIN ODOUR ABNORMAL01 (1.2%)01 (0.3%)      SKIN ULCER1 (1.2%)001 (0.3%)      URTICARIA01 (1.2%)1 (1.2%)2 (0.7%)    SOCIAL CIRCUMSTANCES01 (1.2%)01 (0.3%)      ALCOHOL USE01 (1.2%)01 (0.3%)    SURGICAL AND MEDICAL PROCEDURES2 (2.3%)2 (2.4%)1 (1.2%)5 (1.6%)      ACROCHORDON EXCISION01 (1.2%)01 (0.3%)      CATARACT OPERATION1 (1.2%)01 (1.2%)2 (0.7%)      EYE LASER SURGERY1 (1.2%)001 (0.3%)      SKIN LESION EXCISION01 (1.2%)01 (0.3%)    VASCULAR DISORDERS3 (3.5%)1 (1.2%)3 (3.6%)7 (2.3%)      HOT FLUSH001 (1.2%)1 (0.3%)      HYPERTENSION1 (1.2%)01 (1.2%)2 (0.7%)      HYPOTENSION2 (2.3%)01 (1.2%)3 (1.0%)      ORTHOSTATIC HYPOTENSION1 (1.2%)001 (0.3%)      WOUND HAEMORRHAGE01 (1.2%)01 (0.3%)# }"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_shift_table.html","id":null,"dir":"Reference","previous_headings":"","what":"Create Shift Table — build_shift_table","title":"Create Shift Table — build_shift_table","text":"Shift Tables show progression change baseline, progression often along time; number subjects displayed different range (e.g. low, normal, high) baseline selected time points intervals.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_shift_table.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Create Shift Table — build_shift_table","text":"","code":"build_shift_table(   adsl,   bds_df,   filter_cond = NULL,   trt_var,   trt_label = NULL,   group_var = NULL,   group_label = NULL,   default_view = TRUE )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_shift_table.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Create Shift Table — build_shift_table","text":"adsl (data.frame)adsl data frame. bds_df (data.frame)bds data frame eg. adlb, advs. filter_cond (character) Filtering condition required bds_df. trt_var (character)  Name treatment variable adsl treatment count, eg. ARM. Must vector length 1. trt_label (named vector character) Label trt_var. Must named vector length 1. group_var (vector characters) Names variables grouping addition parameter. Default NULL. group_label (named vector characters) Label group_var. default_view (logical) TRUE (default), values trt_var shown rows, else columns.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_shift_table.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Create Shift Table — build_shift_table","text":"Flextable object Shift Table","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_shift_table.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Create Shift Table — build_shift_table","text":"Parameter Baseline Reference Range Indicator  Placebo (N=86)  Xanomeline High Dose (N=84)  Xanomeline Low Dose (N=84)  HIGH  LOW  NORMAL  HIGH  LOW  NORMAL  HIGH  LOW  NORMAL  n %  n %  n %  n %  n %  n %  n %  n %  n % Alanine Aminotransferase (U/L) HIGH  4 4.6  0 0.0  0 0.0  5 6.0  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  1 1.2 NORMAL  6 7.0  0 0.0  76 88.4  7 8.3  0 0.0  72 85.7  9 10.7  0 0.0  72 85.7 Total  10 11.6  0 0.0  76 88.4  12 14.3  0 0.0  72 85.7  11 13.1  0 0.0  73 86.9 Albumin (g/L) HIGH  0 0.0  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 LOW  0 0.0  2 2.3  0 0.0  0 0.0  0 0.0  1 1.2  0 0.0  1 1.2  0 0.0 NORMAL  4 4.6  0 0.0  80 93.0  0 0.0  0 0.0  82 97.6  1 1.2  0 0.0  82 97.6 Total  4 4.6  2 2.3  80 93.0  1 1.2  0 0.0  83 98.8  1 1.2  1 1.2  82 97.6 Alkaline Phosphatase (U/L) HIGH  5 5.8  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  3 3.6  0 0.0  0 0.0 LOW  0 0.0  0 0.0  4 4.6  0 0.0  0 0.0  1 1.2  0 0.0  1 1.2  0 0.0 NORMAL  4 4.6  0 0.0  73 84.9  5 6.0  0 0.0  77 91.7  4 4.8  0 0.0  75 89.3 Total  9 10.5  0 0.0  77 89.5  6 7.1  0 0.0  78 92.9  7 8.3  1 1.2  75 89.3 Aspartate Aminotransferase (U/L) HIGH  6 7.0  0 0.0  0 0.0  3 3.6  0 0.0  0 0.0  8 9.5  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  8 9.3  0 0.0  72 83.7  6 7.1  0 0.0  75 89.3  8 9.5  0 0.0  68 81.0 Total  14 16.3  0 0.0  72 83.7  9 10.7  0 0.0  75 89.3  16 19.1  0 0.0  68 81.0 Basophils (10^9/L) HIGH  2 2.3  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  0 0.0  0 0.0  81 94.2  0 0.0  0 0.0  82 97.6  0 0.0  0 0.0  83 98.8 Total  2 2.3  0 0.0  81 94.2  0 0.0  0 0.0  82 97.6  0 0.0  0 0.0  83 98.8 Basophils/Leukocytes (FRACTION) HIGH  3 3.5  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 Total  3 3.5  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 Bilirubin (umol/L) HIGH  2 2.3  0 0.0  0 0.0  3 3.6  0 0.0  0 0.0  3 3.6  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  4 4.6  0 0.0  80 93.0  3 3.6  0 0.0  78 92.9  1 1.2  0 0.0  80 95.2 Total  6 7.0  0 0.0  80 93.0  6 7.1  0 0.0  78 92.9  4 4.8  0 0.0  80 95.2 Blood Urea Nitrogen (mmol/L) HIGH  3 3.5  0 0.0  0 0.0  5 6.0  0 0.0  0 0.0  10 11.9  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  9 10.5  0 0.0  74 86.0  8 9.5  0 0.0  71 84.5  13 15.5  0 0.0  61 72.6 Total  12 13.9  0 0.0  74 86.0  13 15.5  0 0.0  71 84.5  23 27.4  0 0.0  61 72.6 Calcium (mmol/L) HIGH  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0 LOW  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  1 1.2  0 0.0  1 1.2  3 3.6 NORMAL  2 2.3  0 0.0  83 96.5  2 2.4  0 0.0  81 96.4  2 2.4  0 0.0  76 90.5 Total  2 2.3  0 0.0  84 97.7  2 2.4  0 0.0  82 97.6  4 4.8  1 1.2  79 94.0 Chloride (mmol/L) HIGH  1 1.2  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  0 0.0 NORMAL  11 12.8  0 0.0  74 86.0  3 3.6  0 0.0  80 95.2  7 8.3  0 0.0  75 89.3 Total  12 13.9  0 0.0  74 86.0  3 3.6  0 0.0  81 96.4  9 10.7  0 0.0  75 89.3 Cholesterol (mmol/L) HIGH  4 4.6  0 0.0  0 0.0  3 3.6  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 LOW  0 0.0  0 0.0  2 2.3  0 0.0  1 1.2  2 2.4  0 0.0  1 1.2  1 1.2 NORMAL  4 4.6  0 0.0  76 88.4  4 4.8  0 0.0  74 88.1  3 3.6  0 0.0  78 92.9 Total  8 9.3  0 0.0  78 90.7  7 8.3  1 1.2  76 90.5  4 4.8  1 1.2  79 94.0 Creatinine (umol/L) HIGH  1 1.2  0 0.0  0 0.0  5 6.0  0 0.0  0 0.0  5 6.0  0 0.0  0 0.0 LOW  0 0.0  0 0.0  2 2.3  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  0 0.0 NORMAL  8 9.3  0 0.0  75 87.2  8 9.5  0 0.0  70 83.3  5 6.0  0 0.0  74 88.1 Total  9 10.5  0 0.0  77 89.5  13 15.5  0 0.0  71 84.5  10 11.9  0 0.0  74 88.1 Creatinine Kinase (U/L) HIGH  4 4.6  0 0.0  0 0.0  9 10.7  0 0.0  0 0.0  7 8.3  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  16 18.6  0 0.0  66 76.7  10 11.9  0 0.0  65 77.4  9 10.7  0 0.0  68 81.0 Total  20 23.3  0 0.0  66 76.7  19 22.6  0 0.0  65 77.4  16 19.1  0 0.0  68 81.0 Eosinophils (10^9/L) HIGH  0 0.0  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  2 2.3  0 0.0  81 94.2  7 8.3  0 0.0  74 88.1  14 16.7  0 0.0  68 81.0 Total  2 2.3  0 0.0  81 94.2  8 9.5  0 0.0  74 88.1  15 17.9  0 0.0  68 81.0 Eosinophils/Leukocytes (FRACTION) HIGH  2 2.3  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  1 1.2  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 Total  3 3.5  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 Ery. Mean Corpuscular HGB Concentration (mmol/L) HIGH  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  3 3.6  0 0.0  0 0.0  8 9.5 NORMAL  0 0.0  0 0.0  86 100.0  0 0.0  0 0.0  80 95.2  0 0.0  0 0.0  75 89.3 Total  0 0.0  0 0.0  86 100.0  0 0.0  0 0.0  83 98.8  0 0.0  0 0.0  83 98.8 Ery. Mean Corpuscular Hemoglobin (fmol(Fe)) HIGH  4 4.6  0 0.0  0 0.0  7 8.3  0 0.0  0 0.0  3 3.6  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  8 9.3  0 0.0  74 86.0  2 2.4  0 0.0  74 88.1  4 4.8  0 0.0  77 91.7 Total  12 13.9  0 0.0  74 86.0  9 10.7  1 1.2  74 88.1  7 8.3  0 0.0  77 91.7 Ery. Mean Corpuscular Volume (f/L) HIGH  5 5.8  0 0.0  0 0.0  6 7.1  0 0.0  0 0.0  10 11.9  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  25 29.1  0 0.0  56 65.1  13 15.5  0 0.0  63 75.0  15 17.9  0 0.0  58 69.0 Total  30 34.9  0 0.0  56 65.1  19 22.6  1 1.2  63 75.0  25 29.8  0 0.0  58 69.0 Erythrocytes (TI/L) HIGH  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 LOW  0 0.0  3 3.5  3 3.5  0 0.0  1 1.2  3 3.6  0 0.0  3 3.6  3 3.6 NORMAL  0 0.0  0 0.0  80 93.0  2 2.4  0 0.0  78 92.9  0 0.0  0 0.0  78 92.9 Total  0 0.0  3 3.5  83 96.5  2 2.4  1 1.2  81 96.4  0 0.0  3 3.6  81 96.4 Gamma Glutamyl Transferase (U/L) HIGH  4 4.6  0 0.0  0 0.0  3 3.6  0 0.0  0 0.0  5 6.0  0 0.0  0 0.0 LOW  0 0.0  0 0.0  2 2.3  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  1 1.2 NORMAL  3 3.5  0 0.0  77 89.5  5 6.0  0 0.0  75 89.3  5 6.0  0 0.0  73 86.9 Total  7 8.1  0 0.0  79 91.9  8 9.5  0 0.0  76 90.5  10 11.9  0 0.0  74 88.1 Glucose (mmol/L) HIGH  1 1.2  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  1 1.2  0 0.0  84 97.7  6 7.1  0 0.0  78 92.9  1 1.2  0 0.0  83 98.8 Total  2 2.3  0 0.0  84 97.7  6 7.1  0 0.0  78 92.9  1 1.2  0 0.0  83 98.8 Hematocrit (1) HIGH  0 0.0  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0  3 3.6  0 0.0  0 0.0 LOW  0 0.0  0 0.0  3 3.5  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  2 2.4 NORMAL  6 7.0  0 0.0  77 89.5  3 3.6  0 0.0  77 91.7  1 1.2  0 0.0  77 91.7 Total  6 7.0  0 0.0  80 93.0  5 6.0  0 0.0  78 92.9  4 4.8  0 0.0  79 94.0 Hemoglobin (mmol/L) HIGH  0 0.0  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0 LOW  0 0.0  3 3.5  4 4.6  0 0.0  1 1.2  0 0.0  0 0.0  4 4.8  3 3.6 NORMAL  2 2.3  0 0.0  77 89.5  3 3.6  0 0.0  78 92.9  0 0.0  0 0.0  75 89.3 Total  2 2.3  3 3.5  81 94.2  5 6.0  1 1.2  78 92.9  2 2.4  4 4.8  78 92.9 Hemoglobin A1C (1) HIGH  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  5 6.0  0 0.0  0 0.0  1 1.2 Total  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  5 6.0  0 0.0  0 0.0  1 1.2 Leukocytes (10^9/L) HIGH  1 1.2  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  1 1.2  2 2.4  0 0.0  1 1.2  1 1.2 NORMAL  5 5.8  0 0.0  80 93.0  5 6.0  0 0.0  76 90.5  7 8.3  0 0.0  74 88.1 Total  6 7.0  0 0.0  80 93.0  5 6.0  1 1.2  78 92.9  8 9.5  1 1.2  75 89.3 Lymphocytes (10^9/L) HIGH  3 3.5  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0 LOW  0 0.0  0 0.0  2 2.3  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  1 1.2 NORMAL  5 5.8  0 0.0  73 84.9  2 2.4  0 0.0  78 92.9  8 9.5  0 0.0  72 85.7 Total  8 9.3  0 0.0  75 87.2  3 3.6  0 0.0  79 94.0  10 11.9  0 0.0  73 86.9 Lymphocytes/Leukocytes (FRACTION) HIGH  0 0.0  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 LOW  1 1.2  0 0.0  1 1.2  0 0.0  0 0.0  0 0.0  0 0.0  1 1.2  0 0.0 NORMAL  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  0 0.0 Total  1 1.2  0 0.0  2 2.3  1 1.2  0 0.0  1 1.2  0 0.0  1 1.2  0 0.0 Monocytes (10^9/L) HIGH  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  5 5.8  0 0.0  78 90.7  2 2.4  0 0.0  80 95.2  4 4.8  0 0.0  78 92.9 Total  5 5.8  0 0.0  78 90.7  2 2.4  0 0.0  80 95.2  5 6.0  0 0.0  78 92.9 Monocytes/Leukocytes (FRACTION) HIGH  3 3.5  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 Total  3 3.5  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 Phosphate (mmol/L) HIGH  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  2 2.3  0 0.0  84 97.7  2 2.4  0 0.0  82 97.6  2 2.4  0 0.0  81 96.4 Total  2 2.3  0 0.0  84 97.7  2 2.4  0 0.0  82 97.6  2 2.4  0 0.0  81 96.4 Platelet (10^9/L) HIGH  2 2.3  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  1 1.2  1 1.2 NORMAL  2 2.3  0 0.0  81 94.2  2 2.4  0 0.0  81 96.4  3 3.6  0 0.0  77 91.7 Total  4 4.6  0 0.0  81 94.2  2 2.4  1 1.2  81 96.4  4 4.8  1 1.2  78 92.9 Potassium (mmol/L) HIGH  1 1.2  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  0 0.0  0 0.0  85 98.8  2 2.4  0 0.0  82 97.6  0 0.0  0 0.0  83 98.8 Total  1 1.2  0 0.0  85 98.8  2 2.4  0 0.0  82 97.6  0 0.0  0 0.0  83 98.8 Protein (g/L) HIGH  1 1.2  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  1 1.2 NORMAL  9 10.5  0 0.0  76 88.4  1 1.2  0 0.0  82 97.6  4 4.8  0 0.0  78 92.9 Total  10 11.6  0 0.0  76 88.4  2 2.4  0 0.0  82 97.6  5 6.0  0 0.0  79 94.0 Sodium (mmol/L) HIGH  3 3.5  0 0.0  0 0.0  4 4.8  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 LOW  1 1.2  0 0.0  1 1.2  0 0.0  0 0.0  3 3.6  0 0.0  0 0.0  2 2.4 NORMAL  10 11.6  0 0.0  71 82.6  10 11.9  0 0.0  67 79.8  9 10.7  0 0.0  73 86.9 Total  14 16.3  0 0.0  72 83.7  14 16.7  0 0.0  70 83.3  9 10.7  0 0.0  75 89.3 Specific Gravity HIGH  3 3.5  0 0.0  0 0.0  3 3.6  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 LOW  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  2 2.4  0 0.0  0 0.0  2 2.4 NORMAL  3 3.5  0 0.0  78 90.7  2 2.4  0 0.0  77 91.7  5 6.0  0 0.0  75 89.3 Total  6 7.0  0 0.0  79 91.9  5 6.0  0 0.0  79 94.0  6 7.1  0 0.0  77 91.7 Thyrotropin (mU/L) HIGH  0 0.0  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0  1 1.2  0 0.0  0 0.0 LOW  0 0.0  3 3.5  0 0.0  0 0.0  3 3.6  0 0.0  0 0.0  1 1.2  0 0.0 NORMAL  1 1.2  0 0.0  82 95.3  0 0.0  0 0.0  80 95.2  0 0.0  0 0.0  82 97.6 Total  1 1.2  3 3.5  82 95.3  1 1.2  3 3.6  80 95.2  1 1.2  1 1.2  82 97.6 Urate (umol/L) HIGH  2 2.3  0 0.0  0 0.0  7 8.3  0 0.0  0 0.0  4 4.8  0 0.0  0 0.0 LOW  0 0.0  0 0.0  1 1.2  0 0.0  1 1.2  0 0.0  0 0.0  1 1.2  1 1.2 NORMAL  2 2.3  0 0.0  81 94.2  2 2.4  0 0.0  74 88.1  2 2.4  0 0.0  76 90.5 Total  4 4.6  0 0.0  82 95.3  9 10.7  1 1.2  74 88.1  6 7.1  1 1.2  77 91.7 Vitamin B12 (pmol/L) HIGH  5 5.8  0 0.0  0 0.0  3 3.6  0 0.0  0 0.0  4 4.8  0 0.0  0 0.0 LOW  0 0.0  3 3.5  1 1.2  0 0.0  2 2.4  0 0.0  0 0.0  4 4.8  0 0.0 NORMAL  0 0.0  0 0.0  77 89.5  0 0.0  0 0.0  79 94.0  0 0.0  0 0.0  76 90.5 Total  5 5.8  3 3.5  78 90.7  3 3.6  2 2.4  79 94.0  4 4.8  4 4.8  76 90.5 pH HIGH  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 LOW  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0  0 0.0 NORMAL  0 0.0  0 0.0  85 98.8  0 0.0  0 0.0  84 100.0  0 0.0  0 0.0  83 98.8 Total  0 0.0  0 0.0  85 98.8  0 0.0  0 0.0  84 100.0  0 0.0  0 0.0  83 98.8","code":"adsl <- pharmaverseadam::adsl |> drop_missing_cols() adlb <- pharmaverseadam::adlb |> drop_missing_cols()  # \\dontrun{ build_shift_table(   adsl = adsl,   bds_df = adlb,   filter_cond = NULL,   trt_var = \"ARM\",   trt_label = c(ARM = \"Description of Planned Arm\"),   group_var = NULL, ,   default_view = FALSE ) #> Joining with `by = join_by(USUBJID, ARM)` .cl-969d4c06{}.cl-96560012{font-family:'Arial';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-9671c216{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-9671c217{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:0;padding-top:0;padding-left:0;padding-right:0;line-height: 1;background-color:transparent;}.cl-9671c218{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-9671c219{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:0;padding-top:0;padding-left:0;padding-right:0;line-height: 1;background-color:transparent;}.cl-9671c21a{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-9671c21b{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:0;padding-top:0;padding-left:0;padding-right:0;line-height: 1;background-color:transparent;}.cl-9671c21c{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-96735ed2{width:3.838in;background-color:transparent;vertical-align: bottom;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96735ed3{width:2.718in;background-color:transparent;vertical-align: bottom;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96735ed4{width:0.079in;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96735ed5{width:0.434in;background-color:transparent;vertical-align: middle;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96735ed6{width:0.561in;background-color:transparent;vertical-align: middle;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96735ed7{width:0.349in;background-color:transparent;vertical-align: middle;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96735ed8{width:0.476in;background-color:transparent;vertical-align: middle;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96735ed9{width:0.646in;background-color:transparent;vertical-align: middle;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96735eda{width:3.838in;background-color:transparent;vertical-align: bottom;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96735edb{width:2.718in;background-color:transparent;vertical-align: bottom;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96735edc{width:0.079in;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673eb68{width:0.434in;background-color:transparent;vertical-align: middle;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673eb69{width:0.561in;background-color:transparent;vertical-align: middle;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673eb6a{width:0.349in;background-color:transparent;vertical-align: middle;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673eb6b{width:0.476in;background-color:transparent;vertical-align: middle;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673eb6c{width:0.646in;background-color:transparent;vertical-align: middle;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673eb6d{width:3.838in;background-color:transparent;vertical-align: bottom;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673eb6e{width:2.718in;background-color:transparent;vertical-align: bottom;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673eb6f{width:0.079in;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673eb70{width:0.434in;background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673eb71{width:0.561in;background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673eb72{width:0.349in;background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673edc0{width:0.476in;background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673edc1{width:0.646in;background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673edc2{width:3.838in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673edc3{width:2.718in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673edc4{width:0.079in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673edc5{width:0.434in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673edc6{width:0.561in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673edc7{width:0.349in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673edc8{width:0.476in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673edc9{width:0.646in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9673edca{width:3.838in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744036{width:2.718in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744037{width:0.434in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744038{width:0.561in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744039{width:0.349in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674403a{width:0.476in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674403b{width:0.646in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674403c{width:3.838in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674403d{width:2.718in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674403e{width:0.434in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674403f{width:0.561in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744040{width:0.349in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674478e{width:0.476in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674478f{width:0.646in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744790{width:3.838in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744791{width:2.718in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744792{width:0.079in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744793{width:0.434in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744794{width:0.561in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744795{width:0.349in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744796{width:0.476in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744797{width:0.646in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96744798{width:3.838in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674e0c2{width:2.718in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674e0c3{width:0.434in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674e0c4{width:0.561in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674e0c5{width:0.349in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674e0c6{width:0.476in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674e0c7{width:0.646in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674e0c8{width:3.838in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674e0c9{width:2.718in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674e0ca{width:0.434in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674e0cb{width:0.561in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9674e0cc{width:0.349in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96757d3e{width:0.476in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96757d3f{width:0.646in;background-color:transparent;vertical-align: top;border-bottom: 0.75pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96757d40{width:3.838in;background-color:transparent;vertical-align: top;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96757d41{width:2.718in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96757d42{width:0.079in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96757d43{width:0.434in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96757d44{width:0.561in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96757d45{width:0.349in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96757d46{width:0.476in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96757d47{width:0.646in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0.75pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-96757d48{width:3.838in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9675dc84{width:2.718in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9675dc85{width:0.434in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9675dc86{width:0.561in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9675dc87{width:0.349in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9675dc88{width:0.476in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9675dc89{width:0.646in;background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9675dc8a{width:3.838in;background-color:transparent;vertical-align: top;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9675dc8b{width:2.718in;background-color:transparent;vertical-align: top;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9675dc8c{width:0.434in;background-color:transparent;vertical-align: top;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9675dc8d{width:0.561in;background-color:transparent;vertical-align: top;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9675dc8e{width:0.349in;background-color:transparent;vertical-align: top;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9675de50{width:0.476in;background-color:transparent;vertical-align: top;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-9675de51{width:0.646in;background-color:transparent;vertical-align: top;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}ParameterBaseline Reference Range IndicatorPlacebo (N=86)Xanomeline High Dose (N=84)Xanomeline Low Dose (N=84)HIGHLOWNORMALHIGHLOWNORMALHIGHLOWNORMALn%n%n%n%n%n%n%n%n%Alanine Aminotransferase (U/L)HIGH44.600.000.056.000.000.022.400.000.0LOW00.000.000.000.000.000.000.000.011.2NORMAL67.000.07688.478.300.07285.7910.700.07285.7Total1011.600.07688.41214.300.07285.71113.100.07386.9Albumin (g/L)HIGH00.000.000.011.200.000.000.000.000.0LOW00.022.300.000.000.011.200.011.200.0NORMAL44.600.08093.000.000.08297.611.200.08297.6Total44.622.38093.011.200.08398.811.211.28297.6Alkaline Phosphatase (U/L)HIGH55.800.000.011.200.000.033.600.000.0LOW00.000.044.600.000.011.200.011.200.0NORMAL44.600.07384.956.000.07791.744.800.07589.3Total910.500.07789.567.100.07892.978.311.27589.3Aspartate Aminotransferase (U/L)HIGH67.000.000.033.600.000.089.500.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL89.300.07283.767.100.07589.389.500.06881.0Total1416.300.07283.7910.700.07589.31619.100.06881.0Basophils (10^9/L)HIGH22.300.000.000.000.000.000.000.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL00.000.08194.200.000.08297.600.000.08398.8Total22.300.08194.200.000.08297.600.000.08398.8Basophils/Leukocytes (FRACTION)HIGH33.500.000.022.400.000.011.200.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL00.000.000.000.000.000.000.000.000.0Total33.500.000.022.400.000.011.200.000.0Bilirubin (umol/L)HIGH22.300.000.033.600.000.033.600.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL44.600.08093.033.600.07892.911.200.08095.2Total67.000.08093.067.100.07892.944.800.08095.2Blood Urea Nitrogen (mmol/L)HIGH33.500.000.056.000.000.01011.900.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL910.500.07486.089.500.07184.51315.500.06172.6Total1213.900.07486.01315.500.07184.52327.400.06172.6Calcium (mmol/L)HIGH00.000.000.000.000.000.022.400.000.0LOW00.000.011.200.000.011.200.011.233.6NORMAL22.300.08396.522.400.08196.422.400.07690.5Total22.300.08497.722.400.08297.644.811.27994.0Chloride (mmol/L)HIGH11.200.000.000.000.000.022.400.000.0LOW00.000.000.000.000.011.200.000.000.0NORMAL1112.800.07486.033.600.08095.278.300.07589.3Total1213.900.07486.033.600.08196.4910.700.07589.3Cholesterol (mmol/L)HIGH44.600.000.033.600.000.011.200.000.0LOW00.000.022.300.011.222.400.011.211.2NORMAL44.600.07688.444.800.07488.133.600.07892.9Total89.300.07890.778.311.27690.544.811.27994.0Creatinine (umol/L)HIGH11.200.000.056.000.000.056.000.000.0LOW00.000.022.300.000.011.200.000.000.0NORMAL89.300.07587.289.500.07083.356.000.07488.1Total910.500.07789.51315.500.07184.51011.900.07488.1Creatinine Kinase (U/L)HIGH44.600.000.0910.700.000.078.300.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL1618.600.06676.71011.900.06577.4910.700.06881.0Total2023.300.06676.71922.600.06577.41619.100.06881.0Eosinophils (10^9/L)HIGH00.000.000.011.200.000.011.200.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL22.300.08194.278.300.07488.11416.700.06881.0Total22.300.08194.289.500.07488.11517.900.06881.0Eosinophils/Leukocytes (FRACTION)HIGH22.300.000.022.400.000.011.200.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL11.200.000.000.000.000.000.000.000.0Total33.500.000.022.400.000.011.200.000.0Ery. Mean Corpuscular HGB Concentration (mmol/L)HIGH00.000.000.000.000.000.000.000.000.0LOW00.000.000.000.000.033.600.000.089.5NORMAL00.000.086100.000.000.08095.200.000.07589.3Total00.000.086100.000.000.08398.800.000.08398.8Ery. Mean Corpuscular Hemoglobin (fmol(Fe))HIGH44.600.000.078.300.000.033.600.000.0LOW00.000.000.000.011.200.000.000.000.0NORMAL89.300.07486.022.400.07488.144.800.07791.7Total1213.900.07486.0910.711.27488.178.300.07791.7Ery. Mean Corpuscular Volume (f/L)HIGH55.800.000.067.100.000.01011.900.000.0LOW00.000.000.000.011.200.000.000.000.0NORMAL2529.100.05665.11315.500.06375.01517.900.05869.0Total3034.900.05665.11922.611.26375.02529.800.05869.0Erythrocytes (TI/L)HIGH00.000.000.000.000.000.000.000.000.0LOW00.033.533.500.011.233.600.033.633.6NORMAL00.000.08093.022.400.07892.900.000.07892.9Total00.033.58396.522.411.28196.400.033.68196.4Gamma Glutamyl Transferase (U/L)HIGH44.600.000.033.600.000.056.000.000.0LOW00.000.022.300.000.011.200.000.011.2NORMAL33.500.07789.556.000.07589.356.000.07386.9Total78.100.07991.989.500.07690.51011.900.07488.1Glucose (mmol/L)HIGH11.200.000.000.000.000.000.000.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL11.200.08497.767.100.07892.911.200.08398.8Total22.300.08497.767.100.07892.911.200.08398.8Hematocrit (1)HIGH00.000.000.022.400.000.033.600.000.0LOW00.000.033.500.000.011.200.000.022.4NORMAL67.000.07789.533.600.07791.711.200.07791.7Total67.000.08093.056.000.07892.944.800.07994.0Hemoglobin (mmol/L)HIGH00.000.000.022.400.000.022.400.000.0LOW00.033.544.600.011.200.000.044.833.6NORMAL22.300.07789.533.600.07892.900.000.07589.3Total22.333.58194.256.011.27892.922.444.87892.9Hemoglobin A1C (1)HIGH00.000.000.000.000.000.000.000.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL00.000.000.000.000.056.000.000.011.2Total00.000.000.000.000.056.000.000.011.2Leukocytes (10^9/L)HIGH11.200.000.000.000.000.011.200.000.0LOW00.000.000.000.011.222.400.011.211.2NORMAL55.800.08093.056.000.07690.578.300.07488.1Total67.000.08093.056.011.27892.989.511.27589.3Lymphocytes (10^9/L)HIGH33.500.000.011.200.000.022.400.000.0LOW00.000.022.300.000.011.200.000.011.2NORMAL55.800.07384.922.400.07892.989.500.07285.7Total89.300.07587.233.600.07994.01011.900.07386.9Lymphocytes/Leukocytes (FRACTION)HIGH00.000.000.011.200.000.000.000.000.0LOW11.200.011.200.000.000.000.011.200.0NORMAL00.000.011.200.000.011.200.000.000.0Total11.200.022.311.200.011.200.011.200.0Monocytes (10^9/L)HIGH00.000.000.000.000.000.011.200.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL55.800.07890.722.400.08095.244.800.07892.9Total55.800.07890.722.400.08095.256.000.07892.9Monocytes/Leukocytes (FRACTION)HIGH33.500.000.022.400.000.011.200.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL00.000.000.000.000.000.000.000.000.0Total33.500.000.022.400.000.011.200.000.0Phosphate (mmol/L)HIGH00.000.000.000.000.000.000.000.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL22.300.08497.722.400.08297.622.400.08196.4Total22.300.08497.722.400.08297.622.400.08196.4Platelet (10^9/L)HIGH22.300.000.000.000.000.011.200.000.0LOW00.000.000.000.011.200.000.011.211.2NORMAL22.300.08194.222.400.08196.433.600.07791.7Total44.600.08194.222.411.28196.444.811.27892.9Potassium (mmol/L)HIGH11.200.000.000.000.000.000.000.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL00.000.08598.822.400.08297.600.000.08398.8Total11.200.08598.822.400.08297.600.000.08398.8Protein (g/L)HIGH11.200.000.011.200.000.011.200.000.0LOW00.000.000.000.000.000.000.000.011.2NORMAL910.500.07688.411.200.08297.644.800.07892.9Total1011.600.07688.422.400.08297.656.000.07994.0Sodium (mmol/L)HIGH33.500.000.044.800.000.000.000.000.0LOW11.200.011.200.000.033.600.000.022.4NORMAL1011.600.07182.61011.900.06779.8910.700.07386.9Total1416.300.07283.71416.700.07083.3910.700.07589.3Specific GravityHIGH33.500.000.033.600.000.011.200.000.0LOW00.000.011.200.000.022.400.000.022.4NORMAL33.500.07890.722.400.07791.756.000.07589.3Total67.000.07991.956.000.07994.067.100.07791.7Thyrotropin (mU/L)HIGH00.000.000.011.200.000.011.200.000.0LOW00.033.500.000.033.600.000.011.200.0NORMAL11.200.08295.300.000.08095.200.000.08297.6Total11.233.58295.311.233.68095.211.211.28297.6Urate (umol/L)HIGH22.300.000.078.300.000.044.800.000.0LOW00.000.011.200.011.200.000.011.211.2NORMAL22.300.08194.222.400.07488.122.400.07690.5Total44.600.08295.3910.711.27488.167.111.27791.7Vitamin B12 (pmol/L)HIGH55.800.000.033.600.000.044.800.000.0LOW00.033.511.200.022.400.000.044.800.0NORMAL00.000.07789.500.000.07994.000.000.07690.5Total55.833.57890.733.622.47994.044.844.87690.5pHHIGH00.000.000.000.000.000.000.000.000.0LOW00.000.000.000.000.000.000.000.000.0NORMAL00.000.08598.800.000.084100.000.000.08398.8Total00.000.08598.800.000.084100.000.000.08398.8# }"},{"path":"https://ahasoplakus.github.io/clinTables/reference/clinTables-package.html","id":null,"dir":"Reference","previous_headings":"","what":"clinTables: Clinical Trial Tables in R — clinTables-package","title":"clinTables: Clinical Trial Tables in R — clinTables-package","text":"Shiny Application visualizing standard tables used Clinical Trials.","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/clinTables-package.html","id":"author","dir":"Reference","previous_headings":"","what":"Author","title":"clinTables: Clinical Trial Tables in R — clinTables-package","text":"Maintainer: Sukalpo Saha sukalposaha@gmail.com","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/drop_missing_cols.html","id":null,"dir":"Reference","previous_headings":"","what":"Drop Columns which has only missing values — drop_missing_cols","title":"Drop Columns which has only missing values — drop_missing_cols","text":"Drop Columns missing values","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/drop_missing_cols.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Drop Columns which has only missing values — drop_missing_cols","text":"","code":"drop_missing_cols(df)"},{"path":"https://ahasoplakus.github.io/clinTables/reference/drop_missing_cols.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Drop Columns which has only missing values — drop_missing_cols","text":"df data frame","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/drop_missing_cols.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Drop Columns which has only missing values — drop_missing_cols","text":"list data frames","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/drop_missing_cols.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Drop Columns which has only missing values — drop_missing_cols","text":"","code":"drop_missing_cols(pharmaverseadam::advs) #> # A tibble: 65,032 x 100 #>    STUDYID  DOMAIN USUBJID VSSEQ VSTESTCD VSTEST VSPOS VSORRES VSORRESU VSSTRESC #>    <fct>    <fct>  <fct>   <dbl> <fct>    <fct>  <fct> <fct>   <fct>    <fct>    #>  1 CDISCPI~ <Miss~ 01-701~    NA <Missin~ <Miss~ <Mis~ <Missi~ <Missin~ <Missin~ #>  2 CDISCPI~ <Miss~ 01-701~    NA <Missin~ <Miss~ <Mis~ <Missi~ <Missin~ <Missin~ #>  3 CDISCPI~ <Miss~ 01-701~    NA <Missin~ <Miss~ <Mis~ <Missi~ <Missin~ <Missin~ #>  4 CDISCPI~ <Miss~ 01-701~    NA <Missin~ <Miss~ <Mis~ <Missi~ <Missin~ <Missin~ #>  5 CDISCPI~ <Miss~ 01-701~    NA <Missin~ <Miss~ <Mis~ <Missi~ <Missin~ <Missin~ #>  6 CDISCPI~ <Miss~ 01-701~    NA <Missin~ <Miss~ <Mis~ <Missi~ <Missin~ <Missin~ #>  7 CDISCPI~ <Miss~ 01-701~    NA <Missin~ <Miss~ <Mis~ <Missi~ <Missin~ <Missin~ #>  8 CDISCPI~ <Miss~ 01-701~    NA <Missin~ <Miss~ <Mis~ <Missi~ <Missin~ <Missin~ #>  9 CDISCPI~ <Miss~ 01-701~    NA <Missin~ <Miss~ <Mis~ <Missi~ <Missin~ <Missin~ #> 10 CDISCPI~ <Miss~ 01-701~    NA <Missin~ <Miss~ <Mis~ <Missi~ <Missin~ <Missin~ #> # i 65,022 more rows #> # i 90 more variables: VSSTRESN <dbl>, VSSTRESU <fct>, VSSTAT <fct>, #> #   VSLOC <fct>, VSBLFL <fct>, VISITNUM <dbl>, VISIT <fct>, VISITDY <dbl>, #> #   VSDTC <fct>, VSDY <dbl>, VSTPT <fct>, VSTPTNUM <dbl>, VSELTM <fct>, #> #   VSTPTREF <fct>, TRTSDT <date>, TRTEDT <date>, TRT01A <fct>, TRT01P <fct>, #> #   ADT <date>, ADY <dbl>, PARAMCD <fct>, AVAL <dbl>, AVALC <fct>, ATPTN <dbl>, #> #   ATPT <fct>, AVISIT <fct>, AVISITN <dbl>, DTYPE <fct>, ONTRTFL <fct>, ..."},{"path":"https://ahasoplakus.github.io/clinTables/reference/run_app.html","id":null,"dir":"Reference","previous_headings":"","what":"Run the Shiny Application — run_app","title":"Run the Shiny Application — run_app","text":"Run Shiny Application","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/run_app.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Run the Shiny Application — run_app","text":"","code":"run_app(   onStart = NULL,   options = list(),   enableBookmarking = NULL,   uiPattern = \"/\",   ... )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/run_app.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Run the Shiny Application — run_app","text":"onStart function called app actually run. needed shinyAppObj, since shinyAppDir case, global.R file can used purpose. options Named options passed runApp call (can following: \"port\", \"launch.browser\", \"host\", \"quiet\", \"display.mode\" \"test.mode\"). can also specify width height parameters provide hint embedding environment ideal height/width app. enableBookmarking Can one \"url\", \"server\", \"disable\". default value, NULL, respect setting previous calls  enableBookmarking(). See enableBookmarking() information bookmarking app. uiPattern regular expression applied GET request determine whether ui used handle request. Note entire request path must match regular expression order match considered successful. ... arguments pass golem_opts. See ?golem::get_golem_options details.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/news/index.html","id":"clintables-010","dir":"Changelog","previous_headings":"","what":"clinTables 0.1.0","title":"clinTables 0.1.0","text":"Initial version. Added NEWS.md file track changes package.","code":""}]
